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ABSTRACT OF DISSERTATION

ANTI-MÜLLERIAN HORMONE IN STALLIONS AND MARES: PHYSIOLOGICAL
VARIATIONS, CLINICAL APPLICATIONS, AND MOLECULAR ASPECTS
Anti-Müllerian hormone (AMH) is a homodimeric glycoprotein that is best known for its
role in regression of the Müllerian duct in the male fetus. Accumulating evidence
indicates that AMH also has an important role during different physiological processes
after birth. In contrast to other species, relatively little is known about AMH in the horse.
In chapter one, developmental and seasonal changes in serum AMH concentrations in
male horses were determined, and the use of AMH for determination of retained
cryptorchid testes was established. In chapter two, the interrelationship between plasma
AMH concentrations, antral follicle counts (AFC), and age in mares was evaluated.
Molecular and hormonal changes in the equine follicle with regard to variations in antral
follicle count and follicular development were examined in chapter three. In chapter four,
the effect of AFC on age-related changes in follicular parameters in light-type horse
mares was examined. Peripheral AMH concentrations were significantly higher in
prepubertal colts than in postpubertal stallions and varied with season in mature stallions
with higher concentrations during the physiological breeding season. Furthermore, serum
AMH concentrations were significantly higher in cryptorchid stallions compared to intact
stallions or geldings. Circulating AMH concentrations varied widely amongst mares of
the same age while the repeatability of AMH was high within and between estrous cycles.
More importantly, AMH concentrations were positively associated with AFC, and this
relationship increased with mare age. In addition, variations in AMH concentrations or
AFC were associated with molecular differences in granulosa cells of growing follicles,
and the expression of AMH and genes co-expressed with AMH in the equine follicle as
well as intrafollicular AMH concentrations decreased during follicular development.
Finally, the inter-ovulatory interval and length of the follicular phase is increased in aged
mares with low AFC. In conclusion, AMH is a useful biomarker for cryptorchidism in
stallions and ovarian reserve in mares. Furthermore, follicular function was interrelated to
AFC or AMH based upon molecular differences in growing follicles, while age-related
changes in follicular parameters are linked to differences in AFC.
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Chapter One: Literature Review
Anti-Müllerian hormone (AMH) belongs to one of the most important reproductive
hormones because of its role in sexual differentiation during fetal development.
Accumulating evidence indicates that AMH also has several important physiological
functions after birth. This review will cover some general aspects of AMH including its
discovery, gene and protein structure, expression pattern, secretion, regulation as well as
the biological activity and function of AMH throughout the reproductive life of males
and females. The primary goal of this review was to focus on AMH in the horse;
nevertheless, some of the described information is derived from other species including
but not limited to cattle, humans, and rodents.

1.1 Anti-Müllerian hormone
1.1.1 The discovery of AMH
The discovery of anti-Müllerian hormone dates back to the middle of last century when
Alfred Jost, a French physiologist, was interested in the process of sexual differentiation.
Initially, he showed that when fetal gonads were removed in utero, the Müllerian ducts
developed while the Wolffian ducts regressed [1]. Consequently, it was assumed that
testosterone played a key role in sexual differentiation, but this was rejected because
administration of androgens to female fetuses resulted in differentiation of the Wolffian
ducts while the Müllerian ducts failed to regress. However, when small pieces of
testicular tissue were grafted in close proximity to the ovary, regression of Müllerian
1

ducts was observed indicating that the fetal testis must have an important role in sexual
differentiation. Therefore, Alfred Jost concluded that the fetal testis does not only
produces androgens but also secretes another substance which induces the regression of
the Müllerian ducts [2]. Although the nature of this substance remained unidentified, he
named it ‘hormone inhibitrice’ which later became better known as Müllerian inhibiting
substance, Müllerian inhibiting factor or anti-Müllerian hormone [3].

1.1.2 Anti-Müllerian hormone: the gene
Cate et al. cloned the bovine and human AMH gene in 1986. The human AMH gene is
2.75 kbp in size, contains five exons, and has a guanine-cytosine content of
approximately 70% [4]. The biological activity of the protein is encoded by the fifth and
last exon of the gene [5]. The location of the AMH gene is different between species. The
AMH gene is located on chromosome 19 in humans [6], chromosome 10 in mice [7], and
chromosome 7 in cattle [8] and in horses (NCBI: gene ID 102148318). Mutations in the
AMH gene can result in persistent Müllerian duct syndrome (PMDS), an autosomal
recessive condition in males in which the Müllerian ducts fail to regress [9]. However,
not all patients with PMDS have a mutation in the AMH gene; this condition can also
arise from a mutation in the AMH receptor gene. Differentiating a mutation in the gene or
gene receptor can be accomplished by measuring circulating AMH concentrations.
Patients with mutations in receptor gene are characterized by normal circulating AMH
concentrations while patients with mutations in the AMH gene usually have undetectable
AMH concentrations. Although the majority of the patients with PMDS have mutations
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in either the AMH gene or receptor, a small percentage of patients (15%) have another
underlying cause that has not yet been identified [10].

1.1.3 Anti-Müllerian hormone: the protein
Although the existence of a substance ‘hormone inhibitrice’ was already implied by
Alfred Jost in 1953, specific information about this substance remained unknown for
quite a while. In one of the first studies on AMH, it was indicated that this substance was
a large molecule, such as polypeptide, as it was not able pass through a membrane which
allowed the passage of androgens [11]. More in depth research showed that this substance
was actually a glycoprotein [12, 13] that contained disulfide bridges as smaller fragments
were obtained when preparations of fetal testes were examined using SDS-page under
reducing conditions [13]. As the methods of AMH purification improved, more detailed
information was obtained about the physical properties of this glycoprotein [14] as well
as its biochemical composition with respect to amino acids and carbohydrates [4, 15].
The protein AMH is derived from a precursor which varies slightly in length among
different species (human, bovine, rat, and mice) ranging from 553 (rat) to 575 (bovine)
amino acids [3]. The equine precursor is similar to the length of the bovine precursor
with 573 amino acids (unpublished data Drs. Ball and Conley; NCBI: GenBank
AEA11205.1). The amino acid sequence of the carboxyl terminal portion of the precursor
is not only highly conserved across different species but also amongst other members of
the transforming growth factor  family. This is in contrast to the amino acid sequence in
the amino-terminal region which is less conserved between different species [3].
3

Furthermore, the bovine AMH precursor starts with a signal sequence (16-17 amino
acids) followed by a pro-sequence (7-8 amino acids). However, both sequences are
cleaved from the precursor before secretion [4]. Finally, dimerization of the remaining
monomer (70 kDa) results in the formation of the glycoprotein AMH which is
approximately 140 kDa [5].
An important characteristic of this 140 kDa AMH glycoprotein is that cleavage is not
required in order to be biologically active. Nevertheless, in vitro cleavage of AMH using
plasmin also results in a biologically active product which contains a 25 kDa and 110
kDa fragment representing the carboxyl and amino terminal dimer, respectively.
Furthermore, sequencing of those fragments revealed that cleavage occurs at the
monobasic cleavage site between the amino acid arginine and serine; 109 amino acids
upstream of the carboxyl-terminus [16]. Interestingly, the biological activity of AMH is
localized in carboxyl terminal fragment whereas the amino terminal fragment is
biologically inactive [17]. Nevertheless, even though this amino terminal fragment is
biologically inactive by itself, it supports the activity of the carboxyl terminal fragment as
more complete regression of Müllerian ducts is observed when both fragments are
included in organ culture media compared to only the carboxyl terminal fragment [18].

1.2 The immunoexpression of AMH in the equine testicular and ovarian tissue
The immunoexpression of AMH in testicular tissue of stallions with regards to testicular
development is well characterized using immunohistochemistry [19]. Similar to other
species [20], the expression of AMH is localized to the cytoplasm of the Sertoli cells. In
4

addition, the expression of AMH is strongly influenced by testicular development as
indicated by the prominent differences in AMH immunolabelling in fetal, pre-pubertal,
post-pubertal equine testicular tissue. As expected, AMH is strongly expressed in the
seminiferous tubules of the fetal testis. Furthermore, AMH is also expressed in Sertoli
cells of prepubertal colts but less than the fetal stage. Finally, the immunoexpression of
AMH disappears during pubertal development as no AMH immunoexpression is present
in testicular tissue of stallions older than 3 years of age [19] (Figure 1.1).

Figure 1.1 The immunoexpression of AMH in testicular tissue of equine fetuses,
prepubertal colts and postpubertal stallions (from left to right). Strong AMH
immunolabelling (arrow) is present within the seminiferous tubules of equine fetal
testicular tissue. AMH expression can also be observed within the presumptive Sertoli
cells (arrowhead) of prepubertal testicular tissue but with reduced intensity. Finally, no
AMH immunoexpression can be detected within the Sertoli cells of seminiferous tubules
of postpubertal stallions (modified from Ball et al.[19])

5

The immunohistochemical expression of AMH has also been examined in the equine
ovary with regard to follicular type and size. The expression of AMH in the equine ovary
is confined to the cytoplasm of the granulosa cells and appears to be largely influenced
by follicular development. No AMH labelling can be detected in the flattened granulosa
cell layer of primordial follicles. The first sign of AMH expression is within the cuboidal
granulosa cells of the primary follicle and the expression of AMH increases as the
number of granulosa cells layers increased (Figure 1.2) [21]. A recent study examined the
expression of AMH in growing follicles (15-20 mm) prior to follicle selection and in
dominant follicles. Strong AMH immunostaining was detected in the small growing
follicles while only faint AMH labelling was present in dominant follicles. This suggests
that AMH is downregulated in the immediate time period around follicle selection.
Another factor that appears to have a large influence on the expression of AMH in equine
ovarian follicles is follicular viability; only weak immunoexpression of AMH is present
in granulosa cells of atretic follicles. Lastly, the equine corpus luteum does not exhibit
any AMH immunostaining [21].
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Figure 1.2 The immunoexpression of AMH in equine primordial, preantral, and antral
follicles (from left to right). No AMH expression is present within primordial follicles
(left image) while mild expression of AMH (arrow) can be detected within the granulosa
cells of a primary follicle (middle image). The expression of AMH increases with
follicular development; granulosa cells of antral follicles (right image) appear to display
stronger AMH labelling (arrowhead) (modified from Ball et al. [21]).

1.3 Changes in circulating concentrations of AMH in males and females
Before describing the regulation of AMH in testicular and ovarian tissue, the reader
should have some understanding about the secretion pattern of AMH throughout the
reproductive life of males and females. The synthesis of AMH in males is initiated early
in fetal life after differentiation of the gonad. The production of AMH by the fetal Sertoli
cells is of crucial importance in the process of sexual differentiation as it induces
regression of the Müllerian ducts [22]. Concentrations of AMH in cord blood of male
human fetuses appear to be high during mid-gestation but declines during the latter part
of pregnancy [23, 24]. After birth, serum AMH concentrations increases and reaches a
peak within the first year of life [25, 26]. Although a slight decrease in AMH
concentrations is observed after one year of age, concentrations of AMH remain high
7

until puberty [25, 26]. The pubertal period is characterized by a rapid decrease in serum
AMH concentrations during the first stage of puberty [27]. As a consequence, only very
low AMH concentrations are present in adult males [25]. Nonetheless, there is still some
variation in AMH concentrations among adult men which is largely determined by
genetic factors [28].

The secretion pattern of AMH is distinctively different in women than in men. Although
AMH expression can be detected in granulosa cells of the fetal ovary during late
gestation [29], no AMH is present in the fetal circulation [24, 30]. Furthermore, AMH
remains undetectable in cord blood in approximately 50 to 80% of the female newborns
[30, 31]. Based on a combination of different studies [30-32], it appears that circulating
AMH concentrations temporarily increases immediately after birth up to three months of
age [31]. This temporary increase in AMH concentration appears to coincide with a
minipuberty period [33]. Another increase in AMH concentration is detected at 4 years of
age [31] and around puberty [32]. After puberty, AMH concentrations remain relatively
stable until the age of 25 [31, 32] after which time AMH starts to decline. A more rapid
decline in AMH concentrations is observed once women reached their 40’s [32]. Finally,
AMH becomes undetectable in the majority of women at the age of 50 or older [31]. It is
well documented that the onset of menopause in women can be reasonably predicted
using circulating concentrations of AMH [34, 35]. Interestingly, it appears that the factor
age only explains 34% of the variation in circulating human AMH concentrations [32].
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1.4 The regulation of AMH
1.4.1 The regulation of AMH in males
It is absolutely mandatory that the testicular expression of AMH is tightly regulated
during early fetal life to ensure normal sexual differentiation. The promoter region of the
AMH gene contains binding sites for several different transcription factors including SF1
(Steroidogenic factor-1) [36], SOX9 [37], and GATA [38] which regulate the expression
of AMH in the fetal testis. Binding of those transcription factors to the promoter region
initiates the transcription of AMH. Furthermore, synergistic actions have been detected
between the different transcription factors [37]. In addition to those transcription factors,
WT-1 (Wilms’ Tumor 1) and DAX-1 are also involved in the regulation of AMH even
though they do not bind to the promoter region of AMH. The expression of AMH is
stimulated through a synergistic effect of WT-1 and SF-1 while DAX-1 inhibits this
synergistic interaction [39].
As indicated earlier, the postnatal expression of AMH in testicular tissue as well as the
secretion of AMH declines at puberty. This decline in AMH at puberty is associated with
anatomical, hormonal and cellular changes which are thought to be involved in the
regulation of AMH. First, the formation of the blood-testis at puberty appears to redirect
the secretion of AMH from the basal compartment of the seminiferous tubule into the
lumen with a decrease in circulating AMH and an increase in seminal plasma AMH as
result [22, 40, 41]. Second, the decrease in AMH concentrations at puberty coincides
with an increase in testosterone concentrations [42]. This inverse relationship between
testosterone and AMH [42] along with an increased AMH expression in testicular tissue
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in the absence of androgen receptors suggests that testosterone has down-regulatory
effect on AMH but requires the presence of androgen receptors [43, 44]. The last factor
that appears to be associated with a decrease in AMH expression at puberty is the process
of meiosis. The expression of AMH in seminiferous tubules appears to be largely
dependent whether or not meiosis is initiated. Once meiosis is initiated, the expression of
AMH in the seminiferous tubule becomes no longer detectable [45, 46].

1.4.2 The regulation of AMH in females
The regulation of AMH in the follicle is not well understood primarily because of the
contradictory results between different studies. Nonetheless, the expression of AMH as
well as the secretion of AMH in follicular fluid is well characterized during different
stages of follicular development. The expression of AMH in granulosa cells and the
concentration of AMH in follicular fluid increases during follicular development until
follicle selection while a rapid decrease in AMH expression and follicular fluid
concentrations are observed after selection of the dominant follicle [47]. Bone
morphogenetic proteins (BMPs) have been identified by several studies as having a
stimulatory effect on the expression of AMH in granulosa cells [48, 49]. In addition to
BMPs, FSH plays a role in regulation of AMH. The effect of FSH on the mRNA
expression of AMH in vitro appears to be different in cattle than in women. In cattle,
FSH has a down-regulatory effect on the expression of AMH mRNA in granulosa cells of
medium sized follicles (5-10mm) as well as on the secretion of AMH by small and
medium sized follicles [49]. In contrast, the AMH mRNA expression in human granulosa
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cells is positively influenced by FSH [50]. Besides FSH, estradiol also appears to be
involved in regulation of AMH. Still, there is some confusion over the regulation of
estradiol and AMH. Two different studies have shown that AMH down-regulates the
expression of aromatase in granulosa cells [51, 52] whereas a recent study showed that
increasing concentrations of estradiol induces a reduction in the mRNA expression of
AMH via estrogen receptor- [53].

1.5 Biological activity of AMH
Two different bioassays based upon different in vitro organ culture systems have been
described to examine the biological activity of AMH [54, 55]. The first method was
based on a pioneering study which revealed that the Müllerian ducts regressed if they
were cultured in vitro with the male fetal gonad in rats [56]. This organ culture system
was later used and modified into a biological assay by Donahoe [54]. Briefly, the
Müllerian and Wolffian ducts were removed from a 14.5 day old fetal rat, separated from
the fetal gonads, cultured in vitro with the sample of interest, embedded in paraffin, and
examined histologically. The degree of regression of the Müllerian duct is evaluated on a
scale from 0 to 5 with grade 5 representing complete regression of the Müllerian ducts
[54]. Interestingly, it has been shown that this method can be used to test biological
material of many different species including the horse [21, 57]. This could potentially be
explained by the fact that the biological activity of AMH is localized to the carboxyl
terminus which appears to be highly conserved across different species. A second method
that has been used to assess the biological activity of AMH in a sample involves the
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measurement of aromatase activity in an ovary culture system which contains a fetal
ovary of a 16 day old rat. An important advantage of this assay is that it provides
quantitative data which can be obtained using lower concentrations of AMH [55].

1.6 Pre- and postnatal biological functions of AMH in males and females
1.6.1 Sexual differentiation: regression of the Müllerian ducts
Without any doubt, the most important biological function of AMH is regression of the
Müllerian ducts in the male fetus. Prior to sexual differentiation, the fetus contains an
undifferentiated gonad along with a pair of Wolffian and Müllerian ducts. In the presence
of the SRY gene, the undifferentiated gonad develops into a testis which begins to
produce AMH and testosterone [58]. The interaction of AMH with the AMH receptor
type II induces a cascade of events that result in the regression of the Müllerian ducts
[59]. In addition, the production of testosterone by the fetal Leydig cells causes the
Wolffian ducts to differentiate into the epididymis, vas deferens, and seminal vesicles. In
the absence of the SRY gene, the undifferentiated gonad develops into a fetal ovary. In
contrast to the testis, the fetal ovary does not produce AMH or testosterone. As result, the
Müllerian ducts develop into the fallopian tube, uterus, cervix and cranial end of the
vagina while the Wolffian ducts regress.

As the gestation length differs between species, the period during gestation when the
regression of the Müllerian ducts is initiated and completed differs. The regression of the
Müllerian ducts is completed by gestational day 17 in rats [54], day 46 in dogs [60] and
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by day 64 in humans [61]. It is unknown when regression of the Müllerian duct is
initiated or even completed in the equine male fetus.

1.6.2 Folliculogenesis
Although regression of the Mullerian duct is a critical feature of AMH during fetal
development, the role of AMH in folliculogenesis is emerging as an important function.
The initial studies examining the function of AMH during folliculogenesis made use of
AMH knock-out mice [62]. First, it was demonstrated that the depletion of the follicular
pool occurred earlier in AMH knock-out mice than in wild-type mice. This rapid decline
in primordial follicles in AMH knock out mice was attributed to an increased rate of
follicular recruitment. Based on these results, it was concluded that the recruitment of
primordial follicles is inhibited by AMH [62, 63]. The negative influence of AMH on the
recruitment of primordial follicles was also examined by assessing follicular growth in
the ovary of newborn mice after ovaries were cultured in vitro with or without AMH.
Indeed, the number of growing follicles was significantly lower in ovaries cultured with
AMH than without AMH [64]. Furthermore, as the number of growing follicles was
increased in AMH knock-out mice, the possibility exists that the growth of FSH-sensitive
follicles was also reduced by AMH [62, 63]. A subsequent study by the same laboratory
clearly showed that the growth of FSH-sensitive preantral follicles in mice is inhibited by
AMH [65]. Likewise, Pellet et al showed that granulosa cells of growing follicles become
less sensitive to FSH in the presence of AMH [66].
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1.6.3 Inhibition of Leydig cell differentiation
As already expected by the relatively high concentrations of AMH in males prior to
puberty, AMH also has an important role during the postnatal period. The first indication
that AMH has an influence on Leydig cell differentiation was provided by Behringer who
showed that testicular tissue in AMH deficient mice is characterized by Leydig cells
hyperplasia [67]. Anti-Müllerian hormone, acting through the AMH receptor on the
Leydig cells, does not only inhibit the differentiation of Leydig cells but also decreases
the steroidogenic activity of Leydig cells. More specifically, AMH appears to have a
down-regulatory effect on the mRNA expression of cytochrome P450 17αhydroxylase/C17-20 lyase in Leydig cells [68]. In accordance to this study, RouillerFabre et al. demonstrated that testicular steroidogenesis is inhibited by
AMH [69].

1.7 Molecular aspects of AMH signaling
Two types of transmembrane serine/threonine kinase receptors are involved in the signal
transduction of AMH, namely AMH receptor type 2 (AMHR2) and AMH receptor type 1.
In contrast to AMHR2, it appears that the AMH receptor type 1 is shared among some
members of TGF-β family. As signal transduction of AMH is mediated through smad 1,
5, and 8, it is likely that AMH shares its type 1 receptor with BMPs which have three
different types of type 1 receptors: ALK2, ALK3, and ALK6. Furthermore, one or more
of these receptors forms a receptor complex with AMHR2 when AMH binds to AMHR2.
After the type 1 receptor is activated, smad 1, 5, 8 are phosphorylated. Subsequently, the
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phosphorylated smad proteins bind to smad 4 and the complex is transported to the cell
nucleus to initiate transcription of the target gene [5].

Copyright @ Anthony N.J. Claes 2014
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Chapter Two: Serum anti-Müllerian hormone concentrations in stallions:
Developmental changes, seasonal variation, and differences between intact stallions,
cryptorchid stallions and geldings
Theriogenology 2013, 79 (9), 1229-35
2.1 Introduction
Anti-Müllerian hormone (AMH) or Müllerian inhibiting substance is a homodimeric
disulfide-linked glycoprotein hormone that belongs to the transforming growth factor-β
superfamily. In males, anti-Müllerian hormone is secreted by the Sertoli cells early in
fetal life where it induces the regression of the Müllerian ducts. Even though its crucial
role in sexual differentiation is accomplished in utero, the secretion of human AMH
persists after birth [3, 22]. The postnatal secretion of human anti-Müllerian hormone is
characterized by high concentrations of AMH during the prepubertal period followed by
a significant decrease at the onset of puberty [25, 27, 70]. Previous studies have described
the expression of AMH in the fetal, prepubertal, postpubertal and cryptorchid equine
testis by immunohistochemistry. The expression of AMH is intense in the Sertoli cells of
the fetal equine testis, decreases in the prepubertal testis with faint to no
immunoexpression in the testis of adult stallions [19, 71]. Changes in serum AMH
concentrations in intact stallions and whether they relate to sexual development have not
yet been reported.

It appears reasonable that season might have an effect on peripheral AMH concentrations
in stallions as numerous endocrine parameters change with season. The secretion of
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gonadotropins, testicular steroids, and proteins is increased during the breeding season,
which reflects an altered activity of hypothalamic-pituitary axis [72]. To date, only one
study in Siberian hamsters suggests a seasonal influence on AMH concentrations as
significantly higher serum AMH concentrations are observed in female hamsters when
they are exposed to long day lengths compared to short day lengths [73]. The presence of
a pronounced seasonal effect in stallions, as described above, would indicate that the
stallion could serve as a good model to examine the effect of season on serum AMH
concentrations.

Diagnostically, anti-Mullerian hormone is also better known for its ability to distinguish
cryptorchidism from anorchia early in prepubertal boys. Because AMH is a Sertoli-cell
derived product, measurable amounts of AMH are indicative of the presence of testicular
tissue [30, 74-76]. The availability of a single, reliable serological test could be of
additional value in the diagnosis of equine cryptorchidism. Ball et al. [19] demonstrated
that the expression of AMH by Sertoli cells in the equine cryptorchid testis persists
beyond puberty which suggests that the measurement of serum AMH might have some
clinical utility in the diagnosis of cryptorchidism. To date, no evidence is available to
support this hypothesis.
The objectives of the study reported here were to (i) validate a commercially available
heterologous enzyme immunoassay for determination of anti-Müllerian hormone
concentrations in the stallion (ii) determine serum anti-Müllerian hormone
concentrations in neonatal colts and fillies, prepubertal colts , and postpubertal stallions,
as well as serum testosterone concentrations in prepubertal colts and postpubertal
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stallions (iii) determine seasonal variations in AMH and testosterone concentrations of
intact mature stallions (iv) determine serum AMH and testosterone concentrations in
geldings, cryptorchid stallions, and intact stallions, and (v) determine seminal plasma
anti-Müllerian hormone concentrations in intact mature stallions.

2.2 Materials and methods
2.2.1 Validation of anti-Müllerian hormone and testosterone assay
Serum concentrations of anti-Müllerian hormone were measured using a commercially
available heterologous sandwich enzyme immunoassay (Active AMH-ELISA;
Diagnostic Systems Laboratories, Webster, TX, USA) per manufacturer’s directions.
Final concentrations of AMH were measured in a dual wavelength mode (450/600 nm)
using a microplate spectrophotometer (BioTek Powerwave HT, Winooski, VT, USA). To
assess dilutional parallelism, serial dilutions of serum from 2 intact stallions were assayed,
and the results obtained were compared to the standard curve. To validate the assay
biologically, serum AMH concentrations were measured daily from 3 intact stallions
immediately before and until 7 days after castration, and the decay in serum AMH was
monitored over time. Furthermore, the biological half-life of AMH was determined by
using the following equation: t1/2 = ln (2) / k where ln represents the natural logarithm,
and k the decay constant. Serum testosterone concentrations were measured by
radioimmunoassay, as previously described by Stabenfeldt et al. [77].
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2.2.2 Serum anti-Müllerian hormone concentrations in neonatal colts and fillies,
prepubertal colts and postpubertal stallions, and serum testosterone concentrations
in prepubertal colts and postpubertal stallions
To characterize circulating AMH concentrations in neonates of different gender and in
the stallion at different developmental stages, serum samples were collected from
newborn fillies (n=5, < 3 days of age), newborn colts (n=8, < 2 days of age), prepubertal
colts (n=8, 13-15 months of age) and postpubertal stallions (n=15, > 2 years of age). All
serum samples were collected during the breeding season from horses boarded at a local
Thoroughbred stud farm or presented to Veterinary Medical Teaching Hospital (VMTH)
at the University of California, Davis (UC Davis). All serum samples were stored at -20C°
until assayed for AMH. Serum samples from prepubertal colts and postpubertal stallions
were also assayed for testosterone. All animal research was conducted under an
Institutional Animal Use and Care committee protocol approved at UC Davis.

2.2.3 Seasonal variations in AMH and testosterone concentrations of intact mature
stallions
Serum samples were collected between 8 and 9 AM on the 14th day of each month from
September 1st, 2010 till August 31st, 2011. Serum samples were stored at -20°C until
assayed for AMH and testosterone. A total of nine intact mature stallions (age range: 822 years of age) were used, including six Quarter Horse stallions, one Thoroughbred, one
Selle Français, and one Appaloosa stallion. All stallions were used in a teaching program
and housed at either the Center for Equine Health (n=5) or at the Department of Animal
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Science (n=4) at UC Davis. All stallions were fed alfalfa hay and had access to water ad
libitum.

2.2.4 Serum anti-Müllerian hormone and testosterone concentrations in geldings,
cryptorchid stallions, and intact stallions
Serum samples were utilized from accessions submitted to the Clinical Endocrinology
Laboratory and clinical cases admitted to the VMTH at the School of Veterinary
Medicine, UC Davis. A total of 97 serum samples were included and classified as
geldings (n= 41), cryptorchid stallions (n= 41) or intact stallions (n= 15) according to
criteria described below. The cryptorchid stallion group included horses with at least one
retained testis regardless the status of the other testis (removed, retained, descended) and
was subdivided into cryptorchid stallions with a scrotal testis (n=8) and without a scrotal
testis (n=33). Only horses 2 years of age or older were included in this part of the study.
Serum samples from the Clinical Endocrinology Laboratory (n=70) were classified solely
according to their history and serum testosterone concentrations. A history of either;
castrated male, castrated male with stallion-like behavior , absence of scrotal testes or
cryptorchid suspect was required in order to be included in the study. Final classification
of those serum samples was based on reference ranges for serum testosterone
concentrations provided by the Clinical Endocrinology Laboratory at UC Davis (gelding:
< 50 pg/mL; cryptorchid stallion: > 100 pg/mL). Classification of horses (n=27)
presented to VMTH was based on a combination of history, clinical findings, testosterone
concentrations, and/or surgery reports.
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2.2.5 Detection of anti-Müllerian hormone in seminal plasma of a stallion and
determination of seminal plasma AMH concentrations in intact stallions
Semen was collected from a stallion of known fertility using an artificial vagina
(Missouri Model) with a built-in filter. A small aliquot of raw semen was centrifuged
(1,500 x g) at 4C° for 5 min, and the supernatant was collected. Approximately 5.4 µg of
seminal plasma protein was separated on 12% sodium dodecyl sulphate-polyacrylamide
gel electrophoresis (SDS-PAGE) and electroblotted onto polyvinylidene fluoride (PVDF)
membranes (Immobilon P, Millipore Corp., Bedford, MA) under non-reducing and
reducing conditions. For analyses in reducing conditions, proteins were heated in the
presence of β-mercaptoethanol. AMH protein was detected with polyclonal antisera
against human recombinant AMH (1:2,500, courtesy of Dr. D. T. MacLaughlin, Boston,
MA, USA). Immunoreactive proteins were detected with HRP-linked IgG (1:10,000) and
luminol reagents with electrochemiluminescence (Amersham, Arlington Heights, IL). To
determine seminal plasma AMH concentrations, semen was collected from 7 additional
stallions in April and processed under the same conditions as described above. The
supernatant was stored at -20C° until analyzed for AMH and protein concentration.
Immediately after the semen collection, serum samples were collected from each stallion
and stored at -20C° until assayed for AMH concentration.

2.3 Statistical analysis
Linear regression analysis was conducted to determine the biological half-life of AMH.
The Mann-Whitney U test was used to compare AMH concentrations between neonatal
colts and fillies because of the small sample size. The Student’s t-test was used to
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compare serum AMH and testosterone concentrations between prepubertal colts and
postpubertal stallions. Because of the skewed distribution of the data, AMH and
testosterone concentrations were log transformed, and a one-way analysis of variance was
used to compare AMH and testosterone concentrations between intact stallions,
cryptorchid stallions, and geldings. Tukey’s test was used to identify significant
differences between individual means. For the seasonal data, testosterone concentrations
were log transformed. A mixed model was used to compare monthly changes in serum
AMH and testosterone concentrations with stallion as a random effect and month as a
fixed effect and differences between individual means were compared using Tukey’s test.
The correlation between serum AMH and testosterone concentrations in the seasonal data
was determined by Pearson correlation coefficient. Because of the small sample size, the
Wilcoxon signed-rank test was used to examine differences between serum and seminal
plasma AMH concentrations. The correlation between serum and seminal plasma AMH
concentrations was determined by a nonparametric correlation (Spearman’s ρ). All
statistical analyses were conducted with JMP (JMP, Version 9.0; SAS Institute; Cary, NC,
USA).

2.4 Results
2.4.1 Validation of the anti-Müllerian hormone assay for stallions
The curves of the serially diluted serum from 2 stallions were parallel to and within the
range of the standard curve for the AMH assay (Figure 2.1). The intra- and inter-assay
coefficients of variation for the AMH assay were 3.1 % and 7.8%, respectively.
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Biological validation of the assay was demonstrated by the exponential decline of serum
anti-Müllerian hormone concentrations in all 3 stallions after castration
(Figure 2.2). The biological half-life of AMH was 1.5 days.

Figure 2.1 Parallelism plot for the anti-Müllerian hormone assay. The curves of the
serially diluted serum samples from two intact stallions are parallel to the standard curve.
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Figure 2.2 Biological validation of the anti-Müllerian hormone assay. Plot natural
logarithm of the mean AMH concentration of 3 stallions against time (day post
castration). Data are expressed as mean ± s.e.m.

2.4.2 Serum anti-Müllerian hormone concentrations in neonatal colts and fillies,
prepubertal colts and postpubertal stallions, and serum testosterone concentrations
in prepubertal colts and postpubertal stallions
Serum AMH concentrations were higher (P<0.005) in neonatal colts (26.4 ± 2.1 ng/mL)
than in neonatal fillies (1.2 ± 0.46 ng/mL). Furthermore, concentrations of AMH were
higher (P<0.02) in prepubertal colts than in postpubertal stallions. In contrast, serum
concentrations of testosterone were lower (P<0.0001) in prepubertal colts compared to
postpubertal stallions (Figure 2.3).
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Figure 2.3 Serum testosterone (black bar) and AMH (gray bar) concentrations in
prepubertal colts and postpubertal stallions. Asterisks above the bars indicate statistical
significance between different age groups (P<0.05). Data are expressed as mean ± s.e.m.

2.4.3 Seasonal concentrations of anti-Müllerian hormone and testosterone in intact
stallions
Overall mean serum AMH concentrations across all stallions and months was 19.8 ± 0.65
ng/mL. There was an effect of time (P< 0.001) on serum AMH concentrations with
significantly higher concentrations in May and June than from September till February
(Figure 4). Serum AMH concentrations peaked in May and reached a nadir in November
with a 1.7 fold difference between peak and nadir concentrations. In contrast, serum
testosterone concentrations varied more widely (Figure 2.4), and the overall mean
concentration of testosterone was 988.4 ± 55.5 pg/mL. Similar to AMH concentrations,
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there was an effect of time (P<0.002) on serum testosterone concentrations. Serum
testosterone concentrations were significantly higher in April, May, and July than in
October. Furthermore, a weak but significant positive correlation (r = 0.27: P<0.006) was
observed between serum AMH and testosterone concentrations.

Figure 2.4 Seasonal variation in AMH (solid line) and testosterone (dashed line)
concentrations in intact stallions (n=9). Serum samples were collected at a monthly
interval. Within AMH and testosterone, means with different superscripts (a,b) differ
(P<0.05). Data are expressed as mean ± s.e.m.
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2.4.4 Serum anti-Müllerian hormone and testosterone concentrations in geldings,
cryptorchid stallions and intact stallions
Mean serum AMH concentration was higher (P<0.004) in cryptorchid stallions than in
intact stallions or geldings (Figure 2.5). In addition, mean serum AMH concentration was
higher (P<0.0001) in intact stallions compared to geldings. Serum AMH concentrations
in geldings were at or below the limit of detection for the assay (Figure 2.5). Serum AMH
concentrations in cryptorchid stallions without a scrotal testis were higher (P<0.007) than
serum AMH concentrations in intact stallions. Serum AMH concentrations tended
(P<0.1) to be higher in cryptorchid stallions without a scrotal testis than in cryptorchid
stallions with a scrotal testis. Finally, no significant differences in serum AMH
concentrations were observed between cryptorchid stallions with a scrotal testis and
intact stallions (Figure 2.6).
As expected, serum concentrations of testosterone were higher (P<0.0001) in intact
stallions (905.4 ± 110.9 pg/mL) compared to cryptorchid stallions (448.3 ± 40.0 pg/mL)
or geldings (22.7 ± 1.3 pg/mL). Serum concentrations of testosterone were also higher
(P<0.0001) in cryptorchid stallions than in geldings.
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Figure 2.5 Mean serum AMH concentration in cryptorchid stallions (n=41), intact
stallions (n=15), and geldings (n=41). Different letters above the bars represent
statistically significant differences (P <0.05). Data are expressed as mean ± s.e.m.
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Figure 2.6 Mean serum AMH concentration in cryptorchid stallions without a scrotal
testis (n=33), cryptorchid stallions with a scrotal testis (n=8), and intact stallions (n=15).
Different letters above the bars represent statistically significant differences (P <0.05).
Data are expressed as mean ± s.e.m.

2.4.5 Detection of anti-Müllerian hormone in seminal plasma of a stallion and
determination of seminal plasma AMH concentrations in intact stallions
Immunoblotting of seminal plasma under non-reducing conditions revealed two
immunoreactive proteins, one at 61 kDa which represents the monomer and another at
120 kDa which represents the dimer. Under reducing conditions, a less prominent band
was observed at 53 kDa and a prominent band around 61 kDa (Figure 2.7).
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No significant differences were observed between seminal plasma AMH concentrations
(49.1 ± 26.7 ng/mL) and their corresponding serum AMH concentrations (18.4 ± 2.7
ng/mL), and there was no significant correlation
(ρ= -0.19, P = 0.65) between serum and seminal plasma AMH concentrations. Mean
seminal plasma AMH was 4.9 ± 2.45 ng/mg seminal plasma protein.

Figure 2.7 Western blot analysis of anti-Müllerian hormone in seminal plasma from a
stallion under non-reducing and reducing conditions. The arrow represents the dimer at
120 kDa whereas the arrow head represents the monomer.
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2.5 Discussion and Conclusion
To the authors’ knowledge, this is the first study to report serum anti-Müllerian hormone
concentrations in neonatal colts and fillies, prepubertal colts and postpubertal stallions,
and changes associated with season or cryptorchidism. The results of our study indicate
that serum AMH concentrations are significantly higher in neonatal colts and prior to
puberty, and that concentrations of AMH vary with season in intact mature stallions.
Moreover, serum anti-Müllerian hormone can serve as a biological marker for the
presence of testicular tissue with higher serum AMH concentrations in cryptorchid
stallions than in intact stallions.

The higher concentrations of AMH in neonatal colts compared to neonatal fillies are not
entirely unexpected as similar sex-related differences in AMH concentrations are
observed in cattle and humans [78, 79]. The secretion of AMH is elevated prior to
puberty as demonstrated by higher concentrations of AMH in prepubertal colts compared
to postpubertal stallions. This finding is consistent with the expression of AMH in fixed
tissue specimens [19, 71]. In addition, significant differences in serum AMH
concentrations between pre- and postpubertal stallions appear to be consistent among
other mammalian species, such as cattle [78, 80] and sheep [81]. Because longitudinal
sampling was not conducted in the present study, the exact period when serum AMH
concentrations started to decline could not be determined. However, serum AMH in
human males decreases at the onset of puberty with a rather rapid decline during the early
stages of puberty [27].
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The decrease in human AMH concentrations during puberty coincides with some
important anatomical, cellular and endocrine changes including the formation of the
blood-testis barrier, meiosis and increasing testosterone concentrations [82]. Similar
changes have been observed at the molecular level during pubertal development of the
stallion. Connexin 43, a gap junctional protein, is more strongly expressed between the
Sertoli cells of the seminiferous tubules after puberty which may reflect changes
associated with the formation of the blood-testis barrier. Moreover, a negative correlation
was present between the stage of development of the seminiferous tubule and the
expression of AMH [71]. Finally, our results indicate that serum AMH concentrations
decrease while testosterone concentrations increase during the transition from the
prepubertal to postpubertal period. These data are consistent with the negative association
between serum AMH and testosterone concentrations as reported to occur during puberty
in humans [42]. However, whether all of the above described changes play an important
role in the down regulation of AMH in the stallion still remains to be determined.

As expected, serum testosterone concentrations were higher in postpubertal stallions than
in prepubertal colts. Significant differences in testosterone concentrations between
prepubertal and postpubertal stallions are most likely due to an increase in testosterone
concentrations during pubertal development. Puberty is characterized by slowly
increasing testosterone concentrations beginning around 68 weeks of age with a rapid
increase in testosterone around 75-80 weeks of age [83, 84].
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Besides differences in AMH concentrations between pre- and postpubertal horses, there
was also a significant seasonal effect on serum AMH concentrations in intact mature
stallions. The increase in AMH concentrations during the spring and summer coincide
with increases in gonadotropins and steroid hormones as previously reported in stallions
[72]. Therefore, seasonal variations of AMH in intact stallions might reflect a Sertoli cell
response to an increased gonadotropic drive. Alternatively, seasonal changes in AMH
concentrations in stallions could reflect the number of Sertoli cells in the testis. The
population of Sertoli cells in stallions is variable as indicated by increasing numbers of
Sertoli cells during the breeding season [85-87] with the largest number present in May
and June [88]. This corresponds well with the peak of serum concentrations of AMH
observed here.

Several studies have shown that serum testosterone concentrations vary with season, with
significantly higher concentrations during the breeding season [89-91]. This seasonal
variation in testosterone concentrations was confirmed by the present study despite the
wide variation in testosterone concentrations throughout the year. We speculate that
environmental cues might be responsible for the wide variability in testosterone
concentrations between different months.

In addition to seasonal changes, serum AMH concentrations were also elevated in
cryptorchids, suggesting that AMH concentrations may be useful in the diagnosis of
cryptorchidism. Moreover, serum concentrations of AMH in geldings were at or below
the limit of detection of the assay suggesting that the testis is the sole source of
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circulating AMH in the stallion whereas testosterone may be synthesized by the adrenal
cortex in addition to the testis [92]. Therefore, serum AMH concentrations might be more
specific for the presence of testicular tissue than serum testosterone. The present study
was not able to determine the sensitivity or specificity of AMH for diagnosis of
cryptorchidism in the stallion because the exact gonadal status of serum samples derived
from the Clinical Endocrinology Laboratory was unknown. However, earlier work in
prepubertal boys reported that anti-Müllerian hormone appears to be more sensitive and
specific than testosterone in the diagnosis of anorchia [74]. Interestingly, serum AMH
concentrations were higher in cryptorchid stallions than in intact stallions. Recently,
Almeida et al. characterized some molecular differences between the cryptorchid and
descended equine testis [93]. The cryptorchid testis resembles in many characteristics the
prepubertal testis as demonstrated by an increased expression of AMH and a reduced
expression of connexin 43. However, further studies into the molecular regulation of
AMH in normal and cryptorchid testes are needed to better understand the genesis of
elevated AMH levels in cryptorchid versus intact stallions of similar ages.

Apart from measurable serum AMH concentrations, we were also able to detect and
measure AMH concentrations in seminal plasma from intact stallions. It has been
speculated that the formation of the blood-testis barrier during puberty results in a shift in
the direction of AMH secretion from the basal compartment into the circulation towards
the seminiferous tubule lumen into seminiferous fluid [22]. As a result, concentrations of
human AMH in seminal plasma exceed serum AMH concentrations [22, 40, 41].
However, the present study did not detect significant differences or even a positive
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correlation between seminal plasma and serum AMH concentrations in the stallion;
seminal plasma AMH concentrations varied widely among different stallions. Even
though AMH is present in seminal plasma of stallions, the biological function of AMH in
seminal plasma still needs to be determined.

In conclusion, our results indicate that serum AMH concentrations are significantly
higher in neonatal colts than in fillies, and higher in prepubertal colts compared to
postpubertal stallions. Besides sex and developmental-related differences, there is a
seasonal variation in AMH concentrations among intact mature stallions with highest
AMH concentrations during the physiological breeding season. Finally, serum AMH
concentrations are higher in cryptorchid stallions than either intact stallions or geldings.
Therefore, anti-Müllerian hormone appears to be a useful biomarker for the presence of
testicular tissue and can serve as a valuable alternative in the endocrine diagnosis of
cryptorchid or monorchid horses.
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Chapter Three: The interrelationship between anti-Müllerian hormone, ovarian
follicular populations, and age in mares
(Equine Veterinary Journal, Accepted)
3.1 Introduction
Anti-Müllerian hormone (AMH) is a granulosa-cell derived hormone that plays a major
regulatory role in female reproduction during folliculogenesis [94]. The recruitment of
primordial follicles [62] as well as the growth of FSH-responsive follicles [65, 66] is
inhibited by AMH. In cows, serum AMH concentrations vary widely among individuals
of similar age and are positively related to the number of antral follicles, better known as
antral follicle count (AFC) [95]. Furthermore, in cattle and in mice, concentrations of
AMH as well as AFC reflect the number of primordial follicles, and both AFC and AMH
serve as biomarkers for follicular reserve [95, 96]. As women age, the size of the
follicular pool declines and eventually becomes depleted at menopause [97]. However,
the age when menopause occurs varies widely among women with corresponding
differences in reproductive lifespan [98]. Among several other factors [99], differences in
the number of primordial follicles in the ovary at birth are thought to contribute to
variation in the reproductive lifespan of females. As AMH is strongly correlated with the
number of primordial follicles [96], and given that the number of primordial follicles
varies widely within females of similar age [95], circulating AMH concentrations appear
to be a better reflection of reproductive age than calendar age [100].
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In contrast to cattle and women, relatively little is known about AMH in the mare. A
previous study in mares showed that the immunoexpression of AMH is restricted to
granulosa cells of the equine ovary and varies with follicular development [21]. With the
exception of primordial and atretic follicles, immunohistochemical labeling for AMH can
be observed in equine granulosa cells of pre-antral and small antral follicles with
increasing intensity as the number of granulosa cell layers increases. In contrast, the
expression of AMH decreases in granulosa cells of ovarian follicles larger than 30 mm
[21]. Anti-Müllerian hormone can be measured in the peripheral circulation of mares
using a heterologous enzyme-linked immunosorbent assay (ELISA) [101]. Although
serum AMH concentrations do not change significantly throughout the estrous cycle of
mares, substantial variation exists between individual mares [101]. Vernunft et al.
showed that plasma AMH concentrations were significantly higher in mares with a high
number of growing follicles than in mares with a low number of growing follicles [102].
As described earlier, reproductive aging is associated with decreasing concentrations of
AMH in mice [96]. Although menopause does not occur in horses, older mares undergo
ovarian senescence which is characterized initially by prolonged follicular phases and
ultimately leads to cessation of ovulation and follicular growth [103]. Interestingly,
ovarian senescence occurs in less than 50% of mares older than 24 years of age [104].
This indicates considerable age differences at the time of follicular depletion which, in
turn, might be represented by differences in AMH concentrations between older mares
based upon their remaining follicular population. Therefore, the objectives of this study
were (i) to determine AFC and plasma AMH concentrations in mares of different ages
and the repeatability within and across estrous cycles, and (ii) to determine the
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relationship between plasma AMH concentrations and AFC with regard to mare age and
follicle size.
3.2 Materials and Methods
3.2.1 Experimental design
All animal procedures in this experiment were performed in compliance with the animal
use protocol approved by the Institutional Animal Care and Use Committee at the
University of Kentucky (#2010-067). A total of 45 light-horse mares of mixed breeds
were included in this study. Mares, kept in pastures, had ad libitum access to grass hay
and water. Mares were classified by age into 3 groups: young (3-8 y, n=10), middle-aged
(9-18 y, n=16), and old (19-27 y, n=19) mares with a mean age of 5.2, 14.2, and 23 years,
respectively. Mares were examined for follicular activity by transrectal palpation and
ultrasonography (Sonoscape S8, Universal Medical Systems Inc, Bedford Hills, NY)
from mid-June to early September. Examinations were performed over two to three
interovulatory intervals on alternate days from ovulation (day 0) till day 14, and then
daily until ovulation. On day 12 of the first, day 6 and 12 of the second, and day 6 of the
third estrous cycle, antral follicle counts were determined in combination with the
determination of plasma AMH concentrations.

3.2.2 Determination of antral follicle counts
Transrectal ultrasonography was used to determine AFC which corresponds to the total
number of antral follicles detected with ultrasound. Mares were sedated with 200 mg
xylazine hydrochloride intravenously (AnaSed®,Llyod laboratories, Shenandoah, IA)
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because AFC determination required mares to stand in stocks for long periods of time
(range: 5-50 min). The ovary was examined systematically with ultrasound starting at the
ovarian pedicle and ending at the ovarian ligament. Sequential ovarian sections were
examined and several cross-sectional image planes of the ovary were frozen for detailed
examination. The largest diameter of all antral follicles as well as the location of each
follicle was recorded on an “ovarian map”. The location of each follicle in relation to
larger follicles as well as real time ultrasonography between the different sections was
used to ensure that follicles were accurately assessed for size and number. In addition,
antral follicles were classified by size into different groups (2-5, 6-10, 11-15, 16-20, 2125, 26-30, 31-35, 36-40, >40 mm). To avoid confusion with other anatomic structures,
only antral follicles with a diameter equal to or larger than 2 mm were recorded. The
ability to accurately determine the number of follicles equal to or larger than 2 mm using
ultrasonography has been previously validated by Ginther and Pierson [105]. All mares
were examined by the same individual during the entire study.

3.2.3 Measurement of plasma anti-Müllerian hormone concentrations
Blood samples were collected into heparinized tubes by venipuncture between 8 and 9
AM and kept on ice until centrifugation. Plasma recovered after centrifugation (1200 x g
for 10 min) was divided into aliquots and stored at -20°C until analyzed for AMH
concentrations. Plasma AMH concentrations were determined using a commercially
available ELISA (MOFA Global AMH ELISA, Verona, WI) per the manufacturer’s
instructions. According to the manufacturer, this assay was developed to measure AMH
concentrations in equine serum and plasma samples. The authors examined serial
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dilutions of plasma samples from 2 mares and assessed parallelism between the dilution
curves and the standard curve (Figure 3.1). A microplate spectrophotometer (BioTek
Powerwave HT, Winooski, VT) was used to read the absorbance at 450 and 630 nm. The
intra- and inter-assay coefficient of variation for anti-Müllerian hormone concentrations
was 6.2%, and 15.8%, respectively. The limit of sensitivity of the AMH assay was 0.017
ng/mL.

Figure 3.1 Parallelism between dilution curves and standard curve of AMH. Serial
dilutions (neat, 1:2, 1:4, and 1:8) of plasma samples from two different mares were
examined and the percent binding (B/Bo in which Bo= maximum binding) of each
diluted sample was determined. Parallelism between the curve derived from serial
dilutions and the standard curve was assessed. The dilution curve of both plasma samples
was parallel to the standard curve.
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3.3 Statistical analysis
For each mare, AFC and plasma AMH concentration from all estrous cycles were
averaged, and mean values were used for subsequent analysis. Differences in AFC and
plasma AMH concentrations between different age groups were determined using the
Kruskal-Wallis test followed by the Wilcoxon test for multiple comparisons to identify
which age groups differ from each other. A Wilcoxon signed rank test was used to detect
differences in AFC between the left and right ovary. The repeatability of AFC and
plasma AMH concentrations within and between estrous cycles was assessed using
Spearman’s rank correlation (ρ) and the Cronbach’s alpha coefficient (α). The
relationship between AFC, plasma AMH concentrations and age was examined using a
mixed model with AMH concentration as a covariate, age group, interaction of AMH by
age group, estrous cycle, estrous cycle day and the interaction of estrous cycle day by
estrous cycle as fixed effects, and mare as a random effect. The variable AFC was square
root transformed to satisfy the assumptions of the mixed model. Correlations between
AFC and AMH concentrations independent of age and within different age groups were
determined using the nonparametric Spearman’s rank correlation (ρ). A mixed model
with mare as random effect was used to determine the relationship between plasma AMH
concentrations and the number of antral follicles within different follicle size groups. The
level of significance was set at P<0.05. Statistical analyses were carried out using JMP
(JMP, V.10.0; SAS Institute; Cary, North Carolina, USA)
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3.4 Results
3.4.1 Antral follicle count and plasma AMH concentrations in mares of different age
groups, and the repeatability within and across estrous cycles
Compared to old mares (median: 13.6 follicles), antral follicle count was higher in young
(P<0.007) (median: 25.5 follicles) and middle-aged (P<0.0006) (median: 27.8 follicles)
mares, but no difference (P=0.4) in AFC was observed between young and middle-aged
mares (Figure 3.2). Furthermore, AFC was higher (P<0.03) for the left ovary than for the
right ovary in mares across all age groups. Plasma AMH concentrations varied widely
within different age groups (Figure 3.3). Although no significant differences were
observed between young (median: 0.29 ng/mL) and middle-aged mares (median: 0.47
ng/mL), plasma AMH concentrations were lower (P<0.008) in old mares (median: 0.21
ng/mL) compared to middle-aged mares
(Figure 3.3).
The repeatability of AFC and plasma AMH concentrations (P<0.0001) was high within
(AFC: ρ=0.96; AMH: ρ=0.91) and between (AFC: ρ=0.87-0.95; AMH: ρ=0.78-0.85)
estrous cycles. Similarly, the overall Cronbach’s alpha coefficient was high (AMH:
α=0.95; AFC: α=0.99) which indicates that AFC and AMH concentrations are consistent
within and between estrous cycles.
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Figure 3.2 Box plots showing antral follicle count (AFC) in young (3-8 y), middle-aged
(9-18y) and old (19-27y) mares. The box represents the 25% quartile, median, and 75%
quartile, whereas the lower whiskers represent the 25% quartile – 1.5*(interquartile
range) and the upper whisker represents the 75% quartile + 1.5*(interquartile range).
Outliers are indicated by individual dots. Antral follicle count was significantly higher in
young and middle-aged mares than in old mares. Different letters above the box plots
indicate statistically significant differences. Significance was set at P<0.05.
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Figure 3.3 Box plots of plasma anti-Müllerian hormone (AMH) concentrations in young
(3-8y), middle-aged (9-18y) and old (19-27y) mares. The box represents the 25%
quartile, median, and 75% quartile, whereas the lower whiskers represent the 25%
quartile – 1.5*(interquartile range) and the upper whisker represents the 75% quartile +
1.5*(interquartile range). The individual dot indicates an outlier. Plasma AMH
concentrations were lower (P<0.008) in older mares than in middle-aged mares. Different
letters above the box plots indicate statistically significant differences. Significance was
set at P<0.05.
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3.4.2 Relationship between AFC and plasma AMH concentrations with regard to
age and follicle size
Analysis of the mixed model (P<0.0001, r2=0.97) indicated that AFC was significantly
related to the concentration of AMH (P=0.0004) and age group (P=0.003), as well as the
interaction of AMH by age group (P=0.003). Estrous cycle (P=0.7), estrous cycle day
(P=0.8) and the interaction of estrous cycle day by estrous cycle (P=0.9) were not related
to AFC. Across all mares, AFC was positively (ρ=0.77) correlated (P<0.0001) with the
concentration of AMH (Figure 3.4), and this relationship was influenced by age group as
shown by the higher correlation coefficient in older (ρ=0.86; P<0.0001) mares than in
middle-aged (ρ=0.60; P=0.01) mares (Figure 3.5). In contrast, the correlation (ρ=0.40)
between AFC and AMH was not significant in young mares (Figure 3.5).
Finally, analysis of statistical model (P<0.0001, r2=0.89) showed that plasma AMH
concentrations were positively associated (P < 0.05) with the number of antral follicles
for follicles between 6 and 20 mm in diameter; whereas, the number of follicles between
2 and 5 mm (P=0.2) or greater than 20 mm (P>0.2) were not associated with plasma
AMH concentrations.
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Figure 3.4 Correlation between AFC and plasma AMH concentration independent of
mare age. The black dots represent mean AFC and AMH concentrations. Antral follicle
count is positively correlated (ρ=0.77, P<0.0001) with plasma AMH concentrations.
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Figure 3.5 Correlations between AFC and plasma AMH concentration within different
age groups (shown from left to right: young (3-8y), middle-aged (9-18y) and old (19-27y)
mares). The black dots represent the mean AFC and AMH concentrations. The Spearman
correlation coefficient was higher in older (ρ=0.86, P<0.0001) mares than in middle-aged
(ρ=0.60, P=0.01), while no significant correlation (ρ=0.40, P<0.4) was detected in young
mares.

3.5 Discussion and Conclusion
To the authors’ knowledge, this is the first report that describes the interrelationship
between AFC, peripheral AMH concentration and age in mares. Our results indicate that
antral follicle count was strongly correlated with plasma AMH concentrations in old
mares and that plasma AMH concentrations were significantly related to the number of
small antral follicles between 6 and 20 mm in diameter. Furthermore, antral follicle count
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was significantly lower in older mares than in young and middle-aged mares and plasma
AMH concentrations were significantly lower in old mares than in middle-aged mares.

The positive correlation between AFC and AMH concentrations has also been described
in cattle [95], mice [96], and women [106-108], and likely reflects the follicular origin of
anti-Müllerian hormone. Contrary to studies in other species, the present study examined
the relationship between AFC and AMH across different age groups. Interestingly, the
correlation between AFC and AMH differed by mare age with a strong correlation in old
mares, a moderate correlation in middle-aged mares, and no significant correlation
between AFC and AMH in young mares. Whether this finding reflects a biological
difference for the horse compared to other species reported to date remains to be
determined.
For the mare, circulating AMH concentrations were associated with the number of antral
follicles between 5 and 21 mm in diameter. In women, approximately 60% of circulating
human AMH is derived from antral follicles between 5 to 8 mm, which corresponds to
follicles up to the time of follicular deviation in women [47]. The comparable follicular
diameter in mares is approximately 11-17 mm [109]. Circulating concentrations of AMH
in mares were not significantly influenced by the number of antral follicles larger than 20
mm. This might be explained by a limited number of follicles larger than 20 mm
compared to other follicle size classes. However, more importantly, it might suggest that
the secretion of AMH by follicles larger than 20 mm subsided around follicle deviation, a
process initiated when the two largest follicles reach a diameter of 19.0 and 22.5 mm
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[110]. Indeed, it has been shown in women that the expression of AMH as well as
follicular fluid concentrations of AMH decreases rapidly after follicle selection [47].

The lower number of antral follicles in older mares, as observed in the study, likely
reflects an age-related reduction in follicular reserve. Similarly, Ginther et al. showed
that number of follicles smaller than 20 mm per follicular wave was significantly lower in
older mares compared to young mares [111]. Furthermore, the wide variation in antral
follicle counts within age groups suggests inherent differences in the population of
ovarian follicles among mares. Indeed, the number of primordial follicles in young mares
was estimated to range from 5600 to 75000 [112]. Data in mice indicate that the number
of growing and primordial follicles is strongly correlated to each other as well as to AMH
and that both parameters decrease with maternal age [96]. This finding is supported in
cattle as AFC is strongly associated with concentrations of AMH and primordial follicle
count [95]. Based on these results together with the significant correlation between AFC
and AMH in middle-aged and older mares, we speculate that anti-Müllerian hormone can
provide valuable information in the assessment of ovarian reserve in middle-aged and
older mares. The ability to assess ovarian reserve could have some clinical utility in
mares experiencing early signs of ovarian senescence such as prolonged or even erratic
interovulatory intervals. As in sheep [113] and in women [114], plasma AMH
concentrations were highly repeatable within and between consecutive estrous cycles.
This, together with the relatively long biological half-life [115], suggests that AMH is a
consistent and useful biological marker of ovarian function.
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Finally, data in cattle, ewes and goats suggest that variations in AMH concentrations
reflect differences in fertility [116-118]. Anti-Müllerian hormone concentrations are
positively associated with the response to superovulatory agents [119] and the number
embryos recovered from superovulated cows [120, 121] and does [118]. Furthermore,
first service conception rate is positively related to the prepubertal AMH concentrations
in ewes [117]. In women, concentrations of AMH have been used to predict the success
of assisted reproductive technology procedures [122-124]. However, AMH does not
appear to be a good predictor in younger women [125, 126]. Whether these findings can
be extrapolated to mares still remains to be determined.

In summary, a positive correlation exists between AFC and plasma AMH concentration
which is influenced by age as indicated by a strong and moderate correlation in old and
middle-aged mares, respectively. Finally, circulating AMH concentrations are primarily
influenced by the number of antral follicles between 6 and 20 mm in diameter.
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Chapter Four: Molecular and hormonal differences in the equine follicle in relation
to variations in antral follicle count and stage of follicular development

4.1 Introduction
Folliculogenesis is a complex and dynamic process regulated by various factors and
hormones signaling via autocrine, paracrine, and endocrine pathways. One of the
hormones that plays an important role in this process is anti-Müllerian hormone (AMH),
a glycoprotein that is synthesized by the granulosa cells of the ovary and secreted into the
peripheral circulation [3]. Circulating AMH concentrations vary widely between mares
[101], and this wide variability in AMH is mainly attributed to differences in antral
follicle counts (AFC) indicating the potential usefulness of AMH as marker for ovarian
reserve [127]. In cattle, increasing amount of data indicate that differences in the number
of antral follicles are not only a reflection of ovarian reserve but are also related to
follicular function [128-130]. Foremost, distinct differences in the mRNA expression of
steroidogenic enzymes and intra-follicular steroid concentrations have been observed in
cows with low and high antral follicle counts [129, 130]. More specifically, the mRNA
expression of aromatase in granulosa cells as well as follicular fluid estradiol
concentrations is increased in growing follicles of cows with a low number of antral
follicles [130] while the mRNA expression of 17α-hydroxylase in theca cells of growing
follicles is decreased in cows with low AFC [129]. Secondly, it has been shown that the
mRNA expression of the FSH receptor (FSHR) in granulosa cells as well as the
responsiveness of granulosa cells to FSH is reduced in cows with low AFC compared to
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cows with high AFC [128]. To the authors’ knowledge, follicular function in mares has
never been linked to AFC or to circulating AMH concentrations.
Equally important, but not well documented, are molecular and hormonal changes in the
equine follicle during follicular development with regards to AMH. In women,
concentrations of AMH in follicular fluid decrease with follicular development [47, 131],
and follicular AMH concentrations are negatively correlated with the mRNA expression
of aromatase and intra-follicular estradiol concentrations [47, 132]. Furthermore, in vitro
studies demonstrated that AMH reduces the expression of aromatase in granulosa cells
[51, 52]. A recent study, however, revealed that increasing estradiol concentrations
reduces the expression of AMH mRNA through the action of estradiol via estrogen
receptor beta (ESR2) [53]. Thus, there is still some confusion regarding the interaction of
AMH, estradiol, and aromatase in the follicle. Follicle-stimulating hormone acting
through the FSHR also plays a role in the regulation of AMH; however, it is unclear
whether FSH has a stimulatory or inhibitory effect on the expression or synthesis of
AMH [49, 50]. Although several regulatory factors for AMH have been identified in
other species, data regarding the regulation of AMH in the equine follicle are lacking.
Identifying genes that are co-expressed with AMH in the equine follicle and genes that
are differentially regulated during follicular development will provide insight regarding
the regulation of AMH in the equine follicle. Therefore, the objectives of this study were
(i) to examine molecular and hormonal differences in growing and dominant equine
follicles in relation to variations in AFC and plasma AMH concentrations (ii) to identify
genes co-expressed with AMH in granulosa cells of growing and dominant follicles, and
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(iii) to examine molecular and hormonal differences in the equine follicle in relation to
the stage of follicular development.

4.2 Materials and Methods
4.2.1 Animal tissue collection
All animal procedures were approved by the Institutional Animal Care and Use
Committee (Protocol: #2010-067) of the University of Kentucky. Cyclic mares (n=30) of
mixed breeds (mean (± sem) age: 15.6 ± 1.4 years; age range: 3-27 years) were examined
by transrectal ultrasonography. Beginning at ovulation, two dimensions (width and
height) of the six largest follicles were recorded every other day to track follicular waves.
When follicular growth was identified, ultrasonographic examinations were performed
daily until euthanasia and tissue collection. A single blood sample was collected six days
after ovulation for determination of plasma AMH concentrations, and AFC was
determined as previously described [127]. Mares were euthanized either prior to follicle
deviation (n=17 mares) when follicular growth was identified and the largest growing
follicle, as identified by ultrasonography, reached a diameter between 15 and 20 mm or
after follicle deviation during estrus (n=13 mares) when endometrial edema was present
and the dominant follicle reached a diameter of 35 mm.
Ovaries were processed using a protocol similar to that described by Evans et al. [133].
Briefly, ovaries were removed immediately after euthanasia and kept on ice. The oviduct
and connective soft tissue was dissected away from the ovary, and the ovary was rinsed
with ice cold PBS. Depending on when the mare was euthanized, either small, growing
53

follicles (n = 1 to 4) or the dominant follicle (n = 1) was identified using a previously
constructed ovarian map to confirm localization and identity of the follicle(s). Follicular
fluid was aspirated with a 25G needle, snap frozen in liquid nitrogen, and stored at -80°C
until processing. The follicle was bisected using a scalpel blade and a small section (full
thickness) of intact follicular wall was retrieved and fixed in formalin for histology and
immunohistochemistry. The theca-basement membrane-granulosa cell layer of the
remaining ovarian follicle was peeled away and transferred to a Petri dish containing cold
RNAlater® (Invitrogen, Carlsbad, CA). Granulosa cells were scraped off the basement
membrane and theca layer using a cell scraper (Fisher Scientific, Waltham, MA). The
stripped granulosa cells in RNAlater® (Invitrogen) were aspirated, transferred to a
cryovial, and stored at 5°C for 24 h before subsequent storage at -80°C. The remaining
tissue, basement membrane and theca cell layer, was transferred to another cryovial
containing RNAlater®, and stored under similar conditions. The combination of the
basement membrane and theca cell layer will be referred as “theca cells” for the
remainder of the study.

4.2.2 Histology
Formalin-fixed intact follicular wall was embedded in paraffin and paraffin blocks were
sectioned (6 µm) for histology and immunohistochemistry. Sections were mounted on
microscope slides, heat fixed (37 °C for 6 hours), and stained with hematoxylin and eosin
for histology. Slides were examined (400x) with bright-field microscopy (Zeiss Axio
Imager Upright Microscope, Carl Zeiss MicroImaging GmbH, Göttingen, Germany).
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Viable follicles were distinguished from atretic follicles using the criteria described by
Kenney et al. [134]. Follicles with signs of atresia were excluded from the study. One
viable follicle per mare was identified from which granulosa and theca cells were used
for further analyses.

4.2.3 RNA extraction and Real-time Reverse Transcriptase Polymerase Chain
Reaction (qRT-PCR)
Granulosa and theca cells stored in RNAlater® were thawed on ice. Extraction of total
RNA from granulosa cells and theca cells was performed using TRIzol® reagent
(Invitrogen). For granulosa cells, RNAlater® was diluted (1:1) with phosphate-buffered
saline (PBS) to decrease its viscosity prior to centrifugation (2000 x g; 5 min).
Immediately after centrifugation, the supernatant was removed and 1 mL of TRIzol®
reagent was added to the granulosa cell pellet. Theca cells were removed from RNA
later® and transferred to a 5-mL cryovial tube that contained 1 mL of TRIzol® reagent.
All subsequent steps performed are described in the TRIzol protocol provided by the
manufacturer. The purity of total RNA isolated from granulosa and theca cells was
analyzed using the Nanodrop 2000 spectrophotometer (Thermo Scientific). All RNA
samples were diluted with RNase-free water to a total volume of 150 µL, and precipitated
by adding 150 µL of isopropanol and 15 µL of sodium acetate (pH=6.1) for at least 24 h.
Following precipitation, RNA samples were centrifuged (12,000 x g; 10 min), washed
with 75% ethanol, centrifuged (12,000 x g; 5 min), air dried, and re-suspended with
RNase-free water. The purity of RNA was re-evaluated with the Nanodrop 2000
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spectrophotometer. Only RNA samples with a 260/280 and 260/230 ratio between 1.7
and 2.3 were included in the study.
To digest contaminating DNA, 2 µg of total RNA was DNase-treated using a DNAfree™ Kit (Invitrogen). Subsequently, 2 µg of DNase-treated total RNA was reverse
transcribed to cDNA using TaqMan® Reverse transcription reagents (Invitrogen) which
contains a mix of RNase-free water, 10X Taqman RT Buffer, 25mM Magnesium
Chloride, deoxyNTPs mixture (2.5mM), random hexamers (50 µM), RNase inhibitor
(20/L), and Multiscribe™ Reverse transcriptase (50 U/µl). Thermal cycler conditions of
the reverse transcription reaction were: 25°C for 10 min, 48°C for 30 min, and 95°C for
5 min.
Real-time PCR was used to examine the expression of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), actin beta (ACTB), anti-Müllerian hormone (AMH), antiMüllerian hormone receptor type 2 (AMHR2), estrogen receptor 1 (ESR1), estrogen
receptor 2 (ESR2), follitropin receptor (FSHR), luteinizing hormone/choriogonadotropin
receptor (LHCGR), insulin-like growth factor 1 (IGF1), inhibin alpha (INHA), inhibin
beta A (INHBA), and clone A17 cytochrome P450 aromatase (CYP19A1) in granulosa
cells of growing and dominant follicles. The expression of GAPDH, ACTB, LHCGR,
cytochrome P-450 17 alpha-hydroxylase/C17,20-lyase (CYP17A1), and steroidogenic
acute regulatory protein (STAR) was examined in theca cells of growing and dominant
follicles. Primers were designed using the primer design tool of the National Center for
Biotechnology Information (NCBI), and their corresponding sequences are shown in
table 4.1. Real-time PCR of duplicate samples was performed using the 7900HT Fast
real-Time PCR System (Applied Biosystems). Reactions contained a combination of
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cDNA (25 ng), primers, and a SYBR Green Master Mix (Invitrogen). Cycle parameters
of polymerase chain reaction were: 95°C for 10 min, followed by 40 cycles of 95°C for
15 sec and 60°C for 1 min, and then a dissociation step of 95°C for 15 sec. Melting
curves for each sample were assessed to evaluate the specificity of the reaction.

Individual primer efficiencies for all the samples were obtained using LinRegPCR [135].
The ΔCT for each gene of interest was calculated by subtracting the CT of the
housekeeping gene from the CT of the gene of interest. In a preliminary experiment, the
expression stability of 4 different housekeeping genes (GAPDH, ACTB, glucuronidase
beta, and beta-2-microglobulin) in granulosa and theca cells was examined using
Normfinder software [4]. The combination of GAPDH and ACTB was identified as the
most stable reference transcripts (data not shown). Data analysis was performed using the
2-ΔΔCt method as described by Livak and Schmittgen [136]. The average ΔCT of all
dominant follicles was used as a calibrator. Gene expression data are presented as RQ
(relative quantification) values. Finally, all obtained PCR products were purified using
the GeneJET PCR Purification Kit (Thermo Scientific), and the size of the purified PCR
products was confirmed using gel electrophoresis (4% agarose gel).
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Table 4.1 Gene, tissue type: granulosa (G) versus theca (T) cells, NCBI reference sequence of the transcript, primer sequence of the
forward and reverse primer, and PCR primer efficiency.
Gene

G /T NCBI reference sequence transcript

Primer sequence of the forward and reverse primer

PCR efficiency

GAPDH

G, T

Forward: 5’ - AGAAGGAGAAAGGCCCTCAG - 3’

2.03

NM_001163856.1

Reverse: 5’ - GGAAACTGTGGAGGTCAGGA - 3’
ACTB

G, T

NM_001081838.1

Forward: 5’ - CGACATCCGTAAGGACCTGT - 3’

1.99

Reverse: 5’ - CAGGGCTGTGATCTCCTTCT - 3’
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AMH

G

JF330269.1

Forward: 5’ - CCATCTGGAGGAGCCAAC- 3’

1.97

Reverse: 5’ - CCCGTGACAGTGACCTCAG - 3’
AMHR2

G

XM_005611400

Forward: 5’ - CTAGACTTGCGGCCTGACA- 3’

1.96

Reverse: 5’ - GCCCAGCTCTGCCTCATA - 3’
ESR1

G

NM_001081772.1

Forward: 5’ - TCCATGGAGCACCCAGGAAAGC- 3’
Reverse: 5’ - CGGAGCCGAGATGACGTAGCC- 3’

1.99

Table 4.1 (continued)
ESR2

G

XM_001915519.2

Forward: 5’ - CAGTATTCCCAGCAGTGCCA- 3’

1.91

Reverse: 5’ - GCCACAACACATTTGGGCTT- 3’
FSHR

G

S70150.1

Forward: 5’ - GCCATGGCATTGCTGACTGA- 3’

2.01

Reverse: 5’ - ATCTTACAGGTGTGCCAGGAA- 3’
LHCGR

G,T

AY464091.1

Forward: 5’ - GGCACACCATCACCTATGCT- 3’

1.89

Reverse: 5’ - AATTGCTGACACCCACAAGG- 3’
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IGF1

G

NM_001082498.2

Forward: 5’ - TTTCAACAAGCCCACAGGGT- 3’

1.99

Reverse: 5’ - TCCAGCCTCCTCAGATCACA- 3’
INHA

G

NM_001081910.1

Forward: 5’ - AGAGCTGGACCGGGAAATTG- 3’

2.05

Reverse: 5’ - CAAACGCCTGACTCCAGGAT- 3’
INHBA

G

NM_001081909.1

Forward: 5’ - GAGGATGACATCGGCAGGAG- 3’
Reverse: 5’ - CGACAGGTCACTGCCTTCTT- 3’

2.05

Table 4.1 (continued)
CYP19A1

G

AF031520.1

Forward: 5’ - CCACATCATGAAACACGATCA - 3’

2.08

Reverse: 5’ - TACTGCAACCCAAATGTGCT- 3’
CYP17A1

T

D30688.1

Forward: 5’ - GCATGCTGGACTTACTGATCC- 3’

2.01

Reverse: 5’ - CTGGGCCAGTGTTGTTATTG- 3’
STAR

T

NM_001081800.1

Forward: 5’ - AGGAGAACCAGCAGGCAAAC- 3’
Reverse: 5’ - TGCGTTCCACAAGCTCTTCA- 3’

1.98
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4.2.4 Immunohistochemistry
The differential expression of two genes (AMH, CYP19A1) in growing and dominant
follicles identified by qRT-PCR was further confirmed with immunohistochemistry. The
immunoexpression of AMH and P450arom was evaluated in randomly chosen growing
(n=4) and dominant (n=4) follicles using an anti-human AMH antibody (1:100, goat
polyclonal SC-6886, Santa Cruz Biotechnology Inc., Santa Cruz, CA [21]) and an antihuman P450 arom (1:500, rabbit polyclonal generously provided by Dr. Nobuhiro
Harada, Fujita Health University, School of Medicine, Aichi, Japan [137, 138]). All
primary antibodies were diluted with Bond Primary Antibody Diluent (Leica
Biosystems). The Leica BOND-MAX system (Leica Microsystems, Buffalo Grove, IL), a
fully automated system, was used to process all the slides. Briefly, paraffin sectioned
slides were dewaxed and rehydrated prior to heat-induced antigen retrieval using an
EDTA-based (pH 8.9) proprietary solution (Leica Biosystems). Subsequently, all slides
underwent a series of incubation steps using reagents from the Bond Polymer Refine
Detection kit: 3% hydrogen peroxide for 5 min, primary antibody for 15 min, blocking
reagent for 8 min, HRP-labeled polymer for 8 min, and diaminobenzidine substrate for 10
min. Each incubation step was followed by washing step using a 1X wash solution
derived by diluting the Bond Wash Solution 10X concentrate with distilled water.
Negative controls were obtained by omitting the primary antibody.
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4.2.5 Measurement of estradiol and AMH concentrations in follicular fluid of
growing and dominant follicles
Concentrations of estradiol in follicular fluid were measured with a solid-phase,
competitive chemiluminescent enzyme immunoassay (Immulite® 1000 system, Siemens
Healthcare Diagnostics, Los Angeles, CA, USA). Follicular fluid samples were diluted
with estradiol sample diluent (LE2Z, Diagnostics Products Corporation, Los Angeles,
CA, USA) to a ratio of 1:320 – 1:640 for growing follicles and 1:10,000 for dominant
follicles. The sensitivity of the immunoassay was 15 pg/mL, and the intra-assay
coefficient of variation was 15%. Concentrations of AMH in follicular fluid and plasma
were measured with an ELISA (MOFA Global Equine AMH ELISA, Verona, WI, USA)
according to the manufacturer’s instructions. The AMH assay buffer was used to dilute
follicular fluid of growing (1:30) and preovulatory follicles (neat to 1:10). The intra-assay
coefficient of variation for follicular fluid AMH was 12.3 %. Finally, serial dilutions of
follicular fluid were analyzed for AMH and estradiol to assess dilutional parallelism with
the respective standard curves. Concentrations of AMH and estradiol were linear within
the analytic range of the assay and proportional to the dilution factor.

4.3 Statistical analysis
A multiple linear regression model including AFC or plasma AMH concentration, follicle
type (growing versus dominant follicle), mare age, and the interaction of mare age by
follicle type was used to examine whether differences in intrafollicular AMH
concentrations, estradiol concentrations, and mRNA expression of selected genes
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(table 4.1) in granulosa cells or theca cells were associated with AFC or plasma AMH
concentrations. The Pearson correlation coefficient was used to examine mutual
correlations between AFC, plasma AMH concentrations, and the expression of selected
genes (table 4.1) in granulosa cells of growing and dominant follicles. Within each
follicle type, the relationship between follicular diameter and AFC or plasma AMH
concentrations as well correlations between the expression of AMH mRNA and the
expression of other selected genes in granulosa cells were also examined using the
Pearson correlation coefficient. Differences in the expression of selected genes in
granulosa and theca cells between growing and dominant follicles were assessed using an
unpaired t-test. A one-way analysis of variance with a student’s t-test as post hoc test was
used to detect differences between plasma AMH concentrations, follicular AMH
concentrations in growing follicles, and follicular AMH concentrations in dominant
follicles. The unpaired t-test was also used to detect differences in follicular fluid
estradiol concentrations between growing and dominant follicles. Correlations between
intrafollicular AMH concentrations, intrafollicular estradiol concentrations, the mRNA
expression of AMH and the mRNA expression of CYP19A1 in granulosa cells were
examined using the Pearson correlation coefficient. Where needed, variables were square
root or log transformed to satisfy the assumptions of the employed statistical test but
untransformed mean data (± sem) are presented. Statistical analyses were performed
using JMP (JMP version 10.0, SAS Institute; Cary, North Carolina), and statistical
significance was set at P<0.05.
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4.4 Results
4.4.1 Molecular and hormonal differences in growing and dominant equine follicles
in relation to variations in AFC and plasma AMH concentrations.
Antral follicle counts were positively correlated (P<0.001, r=0.79) with plasma AMH
concentrations. Analysis of the overall multiple linear regression model including both
growing and dominant follicles, revealed that the expression of AMH, AMHR2, ESR2,
and INHA in granulosa cells was significantly associated with AFC and plasma AMH
concentrations. The expression of FSHR in granulosa cells was significantly associated
with plasma AMH concentrations, and there was a tendency (P=0.10) for an association
between FSHR and AFC. The expression of ESR1 in granulosa cells was significantly
associated with plasma AMH concentrations but not with AFC. In granulosa cells, there
were no significant associations between the expression of IGF1, INHBA, and CYP19A1
and AFC or plasma AMH concentrations. Mare age was significantly associated with the
expression of AMHR2 and ESR1 in granulosa cells but the interaction of mare age by
follicle type was not significant. The expression of AMHR2 and ESR1 in granulosa cells
increased with mare age. The expression of LHCGR, CYP17A1, and STAR in theca cells
were not significantly associated with AFC or plasma AMH concentrations. In addition,
neither estradiol nor AMH concentrations in follicular fluid were significantly associated
with AFC or plasma AMH concentrations.
Within growing follicles, the expression of AMH, AMHR2, ESR2, and INHA in granulosa
cells was significantly correlated with AFC (Figure 4.1) and plasma AMH concentrations
(Figure 4.2). In addition, the expression of ESR1 and FSHR was significantly associated
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with plasma AMH concentrations and had a tendency to be correlated with AFC. In
contrast to growing follicles, no significant correlations were observed in dominant
follicles (data not shown). Within each follicle type, there was no relationship between
follicular diameter and AFC or plasma AMH concentration.

Figure 4.1 Pearson’s correlations (r) between AFC and the expression of genes involved
in follicular development (AMH, AMHR2, ESR1, ESR2, FSHR, LHCGR, IGF1,
INHBA, INHA) and steroidogenesis (CYP19A1) in granulosa cells of growing follicles.
The expression of genes is shown as RQ values. Note that the Y-axis scale is different for
the expression of AMH, and therefore is plotted individually.
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Figure 4.2 Pearson’s correlations (r) between plasma AMH concentrations and the
expression of genes involved in follicular development (AMH, AMHR2, ESR1, ESR2,
FSHR, LHCGR, IGF1, INHBA, INHA) and steroidogenesis (CYP19A1) in granulosa
cells of growing follicles. The expression of genes is shown as RQ values. Note that the
Y-axis scale is different for the expression of AMH, and therefore is plotted individually.

4.4.2 Identification of genes co-expressed with AMH in granulosa cells of growing
and dominant follicles
Correlations between the expression of AMH and the expression of genes involved in
follicular development (AMHR2, ESR1, ESR2, FSHR, LHCGR, IGF1, INHA, INHBA)
and steroidogenesis (CYP19A1) were examined in granulosa cells of growing and
dominant follicles (Table 4.2). In granulosa cells of growing follicles, the expression of
AMH was strongly correlated with the expression of AMHR2 and INHA. In addition, a
moderate to strong correlation was observed between the expression of AMH and the
expression of ESR2 and FSHR. In contrast, no significant correlations were observed in
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granulosa cells of dominant follicles with the exception that the expression of AMH had a
tendency to be moderately correlated with the expression of ESR2.

Table 4.2 Pearson’s correlations (r) between the expression of AMH mRNA and the
expression of genes involved in follicular development (AMHR2, ESR1, ESR2, FSHR,
LHCGR, IGF, INHA, INHBA) and steroidogenic genes (CYP19A1) in granulosa cells of
growing and dominant follicles.
Gene

Gene

Granulosa cells of

Granulosa cells of

transcript

transcript

growing follicles

dominant follicles

Correlation

P-value

Correlation

P-value

AMH

AMHR2

r=0.76

P=0.0004

r=0.45

P=0.12

AMH

ESR1

r=0.37

P=0.14

r=0.42

P=0.15

AMH

ESR2

r=0.66

P=0.004

r=0.52

P=0.07

AMH

FSHR

r=0.63

P=0.006

r=0.30

P=0.3

AMH

LHCGR

r=-0.36

P=0.2

r=0.34

P=0.3

AMH

IGF1

r=-0.27

P=0.3

r=0.22

P=0.5

AMH

INHA

r=0.70

P=0.002

r=-0.06

P=0.9

AMH

INHBA

r=0.01

P=0.9

r=0.20

P=0.5

AMH

CYP19A1

r=-0.01

P=0.9

r=0.22

P=0.5
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4.4.3 Molecular and hormonal differences in the equine follicle in relation to the
stage of follicular development.
Differences in the expression of selected genes in granulosa and theca cells between
growing and dominant follicles were evaluated. The expression of AMH and several
genes co-expressed with AMH (AMHR2, ESR2, and FSHR) was significantly greater in
granulosa cells of growing follicles than in dominant follicles whereas the expression of
LHCGR, IGF1, INHA, and CYP19A1 was significantly greater in granulosa cells of
dominant follicles (Figure 4.3). Likewise, the expression of CYP17A1 and STAR in theca
cells was significantly higher in dominant follicles than in growing follicles. No
significant differences were detected in the expression of LHCGR in theca cells between
growing and dominant follicles.
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Figure 4.3 The expression (RQ) of selected genes in granulosa cells of growing follicles
(G) prior to follicle deviation and dominant follicles (D) after follicle deviation. Asterisks
above the bars indicate differences (P<0.05) in expression between growing and
dominant follicles. Data are presented as mean ± sem. Note that the Y-axis scale is
different for the expression of AMH.

Two differentially expressed genes (AMH and CYP19A1) in granulosa cells of growing
and dominant follicles identified by qRT-PCR were examined using
immunohistochemistry (Figure 4.4). The immunoexpression of AMH and P450arom was
localized to the cytoplasm of the granulosa cells of growing and dominant follicles.
AMH immunostaining was more intense in granulosa cells of growing follicles whereas
only a faint immunoexpression was detected in granulosa cells of dominant follicles. In
contrast, only slight immunostaining for P450arom was detected in granulosa cells of
growing follicles whereas a more intense immunolabelling for P450arom was observed in
granulosa cells of dominant follicles.
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Figure 4.4 The immunoexpression of AMH and P450arom in granulosa cells of growing
and dominant follicles. Strong AMH immunolabelling is observed in granulosa cells of
growing follicles (A) whereas only faint expression is detected in granulosa cells of
dominant follicles (B). In contrast, only slight P450arom immunostaining was detected in
granulosa cells of growing follicles (C) while the expression of P450arom was more
intense in granulosa cells of dominant follicles (D). The small inset figure in A and C
shows the negative control for that particular antibody.
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Finally, concentrations of AMH were significantly higher in follicular fluid than in
circulating plasma, and follicular fluid AMH concentrations were significantly higher in
growing than in dominant follicles. In contrast, concentrations of estradiol in follicular
fluid were significantly higher in dominant follicles than in growing follicles (Table 4.3).
During follicular development, follicular fluid AMH concentrations were positively
correlated with the expression of AMH mRNA (r=0.80, P<0.0001), and follicular
estradiol concentrations were positively correlated with the expression of CYP19A1
mRNA (r=0.84, P<0.0001). In addition, there was a strong negative correlation (r=-0.84,
P<0.0001) between AMH and estradiol concentrations in follicular fluid. Furthermore,
follicular fluid AMH concentrations were negatively associated with the expression of
CYP19A1 mRNA (r=-0.77, P<0.0001), and follicular fluid estradiol concentrations were
negative associated with the expression of AMH mRNA (r=-0.76, P<0.0001).

Table 4.3 Anti-Müllerian hormone and estradiol concentrations in follicular fluid of
growing and dominant follicles. Data are presented are mean ± sem. Statistically
significant differences (P<0.001) are indicated by the different letters.
Growing follicles

Dominant follicles

(n=17)

(n=13)

Anti-Müllerian hormone

155.7 ± 20.8 ng/mLa

13.5 ± 1.9 ng/mLb

Estradiol

242.0 ± 54.0 ng/mLa

2424.6 ± 217.5 ng/mLb
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4.5 Discussion and conclusion
To our knowledge, this is the first study to examine molecular and hormonal differences
in the equine follicle in relation to AFC, plasma AMH concentrations, and follicular
development. Our results demonstrated that AFC and plasma AMH concentrations were
highly associated and in turn were associated with molecular differences in the growing
equine follicle prior to selection of the presumptive dominant follicle. Furthermore,
several genes (AMHR2, FSHR, and ESR2) were co-expressed with AMH in the growing
equine follicle prior to follicle selection. The expression of these genes decreased during
follicular development coincident with a decrease in mRNA and protein expression of
AMH in the follicle. In contrast, intrafollicular estradiol concentrations increased and
were inversely correlated with intrafollicular AMH concentrations during follicular
development.

It is well established in cows that variations in AFC are associated with differences in
ovarian function and reproductive success [116, 139]. Ovarian response to exogenous
stimulation is reduced [140], and cows with low AFC have significantly lower fertility
rates which may be associated with an increased incidence of aneuploidy in oocytes
[141]. In cows with low AFC, the expression of aromatase in granulosa cells as well as
intrafollicular estradiol concentrations are increased [130] despite a lower expression of
CYP17A1 in theca cells of growing follicles [129]. In addition, the expression of AMH
and FSHR is lower in granulosa cells in cows with low AFC. A reduced expression of
AMH might be a reflection of a diminished oocyte quality [130] while the lower
expression of FSHR is associated with a reduced responsiveness to FSH in cattle and
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women [128, 142]. It is hypothesized that chronically elevated concentrations of
circulating FSH in cows with low AFC may induce refractoriness at the level of the
follicle [128]. In contrast to reports in cattle, the present study reveals that variations in
AFC in mares were not accompanied by molecular and hormonal differences related to
steroidogenesis in growing follicles. Nevertheless, low AFC in the mare appears similar
to women and cows in regards to a reduced expression of AMH and FSHR. The
expression of the AMH receptor (AMHR2) was also lower in granulosa cells of growing
follicles from mares with low AFC or low AMH concentrations. Although little is known
about the autocrine / paracrine regulation of follicular development by AMH, a reduced
expression of AMHR2 might indicate that the AMH signaling pathway is compromised
in mares with low AFC. Additionally, the expression of mRNA for estrogen-receptor β
(ESR2) is also reduced in mares with low AFC which may adversely affect proliferation
and differentiation of granulosa cells and subsequent folliculogenesis in mares with low
AFC. Based upon these observations, low AFC in the mare is associated with molecular
differences in the equine follicle which could have an adverse impact on follicular
function; however, observed changes in aromatase expression and follicular fluid
estradiol concentrations in mares with low AFC were not observed in the present study.

Besides the relationship between AFC, plasma AMH concentrations and molecular
changes in the growing follicle, a number of genes (AMHR2, FSHR, ESR2) known to be
involved in the regulation of AMH were co-expressed with AMH in the growing equine
follicle prior to follicle selection. The co-expression of AMH and AMHR2 might indicate
that autocrine / paracrine signaling plays a role in the regulation of AMH in the equine
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follicle. Also FSH, acting through the FSHR, has an important role in the regulation of
AMH even though there is controversy whether it inhibits or stimulates the production of
AMH. In cattle, FSH had an inhibitory effect on the secretion of AMH in cultured bovine
granulosa cells [49] while in humans, FSH stimulated the transcription of AMH [50]. In
mares, circulating FSH concentrations peak when the diameter of largest growing follicle
is approximately 13 mm and decline thereafter resulting in lower FSH concentrations
during the later stages of follicular development [143]. A similar pattern is observed in
the expression of AMH and FSHR in granulosa cells of the equine follicle; the expression
of AMH and FSHR was higher in the small growing follicle than in the dominant follicle.
Therefore, it is likely that increased FSH concentrations are positively associated with
expression of AMH in the equine follicle which could indicate that FSH has a stimulatory
effect on the expression of AMH in the equine follicle. In addition to FSH, estradiol
appears to regulate AMH expression in the human follicle with a down-regulation of
AMH via estrogen receptor β [53]. Even though the effect of estradiol on AMH in the
equine follicle remains to be determined, our study showed that the mRNA and protein
expression of AMH in granulosa cells and intrafollicular AMH concentrations decreased
during follicular development concomitant with an increase in intrafollicular estradiol
concentrations. Furthermore, the expression of ESR2 in granulosa cells was correlated
with the expression of AMH in growing follicles and had a tendency to be correlated with
the expression of AMH in dominant equine follicles. Therefore, we hypothesize that
increasing concentrations of estradiol act on the ERβ during follicular development with
subsequent down-regulation of AMH in granulosa cells of the equine follicle.
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A number of transcripts examined in this study demonstrated differential regulation
during follicular development as indicated by the significant differences between growing
and dominant follicles. The expression of ESR2 was significantly lower in dominant
compared to growing follicles consistent with data in women [144] and in rats showing
that the expression of ESR2 is down-regulated after the LH surge [145]. Although we did
not measure peripheral concentrations of LH in this study, the relatively long LH surge in
mares [146] combined with an increased expression of LHCGR in granulosa cells of the
dominant follicle led us believe that the LH surge was already initiated in our study.
Similar to ESR2, the expression of FSHR was lower in dominant follicles than in growing
follicles. This lower expression of FSHR in dominant follicles likely coincides with
lower circulating FSH concentrations during the later stages of follicular development
[147]. On the other hand, the expression of IGF1, INHA, and CYP19A1 is increased in
dominant follicles, and likely coincides with increased intrafollicular concentrations of
estradiol, IGF1, and INHA as intra-follicular estradiol, IGF1, and INHA begin to
increase in the future dominant follicle immediately before follicle selection [148]. The
importance of IGF1 during the process of follicle deviation has been well described in the
mare. At the time of follicle deviation, an increase in IGF1 is observed in the dominant
follicle but not in subordinate follicles [148]. Ablation of the largest follicle at the time
follicle deviation results an increase in intra-follicular IGF1 concentrations in the second
largest follicle which subsequently becomes the dominant follicle [149]. Furthermore,
when IGF1 is injected in the second largest follicle around the time of follicle selection,
this injected follicle will develop into the dominant follicle [150]. Thus, the expression of
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several genes in the equine follicles is strongly influenced by the stage of follicular
development.

Finally, in accordance to differences in the gene and protein expression of AMH between
growing and dominant follicles, concentrations of AMH in follicular fluid were
significantly higher in small growing follicles than in dominant follicles. This result
supports a previous study showing that peripheral AMH concentrations are primarily
associated with the number of follicles between 6 and 20 mm [127]. It also indicates that
concentrations of AMH in follicular fluid decrease with increasing follicular size. Indeed,
AMH concentrations are negatively correlated with follicular diameter and become
undetectable in the equine preovulatory follicle [151]. The high follicular AMH
concentrations in growing follicles immediately prior to follicle selection compared to the
very low concentrations in dominant follicles suggests that follicular AMH
concentrations decline rather rapidly after follicle deviation. Studies in women have
shown that follicular AMH concentrations do not decrease linearly throughout follicular
development; a prominent and sharp decrease in AMH concentrations in follicular fluid is
observed when the dominant follicle is selected from a cohort of recruited growing
follicles [47]. The sharp decline in follicular AMH concentrations further suggests that
AMH might play an important role in follicle selection in the horse.

In conclusion, our study demonstrates that variations in AFC and plasma AMH
concentrations are associated with molecular differences in the equine follicle which, in
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turn, may have an impact on follicular function. In addition, the expression of AMH and
genes co-expressed with AMH in the equine follicle as well as intrafollicular AMH
concentrations decrease during follicular development while follicular estradiol
concentrations are inversely related to follicular AMH concentrations.
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Chapter Five: The influence of age, antral follicle count and diestrous ovulations on
estrous cycle characteristics of mares

5.1 Introduction
Aging is an important physiological process that has a negative impact on the
reproductive system [152]. Reproductive aging in mares is associated with a decreased
fertility that has been associated with a variety of factors including a delayed uterine
clearance [153], reduced oocyte quality [154], and a higher rate of early embryonic loss
[155]. Nevertheless, older mares are often bred because of their genetic value and/or
performance and not for their fertility. Therefore, it is not uncommon to encounter aged
broodmares in equine practice. To optimize the reproductive management of these older
mares, veterinarians practicing reproductive medicine should understand which, how, and
when reproductive parameters change with age. Reproductive aging in pony mares is
characterized by prolonged follicular phases, longer inter-ovulatory intervals and
increased circulating FSH concentrations [103, 156, 157]. Compared to light horse mares,
pony mares have longer inter-ovulatory intervals [158], fewer multiple ovulations, and
fewer diestrous ovulations [159]. Because of differences in reproductive parameters
between pony and light-horse mares, extrapolation of findings related to effects of
reproductive aging from the existing studies in ponies to horse mares may not always be
possible.
Aging in mares is also associated with a decrease in the population of antral follicles
[111, 157]. Nevertheless, the number of antral follicles varies widely between aged mares
[160]. As large individual differences in follicular populations exist within the same age
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group, it is important to distinguish reproductive age from chronological age [98, 161].
Therefore, it is possible that some of the age-related changes in follicular parameters are
linked to differences in antral follicle counts (AFC). The number of primordial follicles,
representing the ovarian reserve, decreases with mare age due to a high turnover of
follicles during each follicular wave. The follicular pool eventually becomes depleted
which results in ovulation failure and cessation of estrous cycles [162]; however, the age
at which ovarian senescence occurs varies widely between older mares [104] suggesting
that there are inherent differences in the number of primordial follicles between mares of
the same age along with an age-related decline in primordial follicles,

Mare age is not the only factor that has an impact on different parameters of the estrous
cycle. The occurrence of major secondary follicular wave is also associated with changes
such as a prolonged inter-ovulatory interval and a delay in the emergence of the primary
follicular wave. [163, 164]. A major secondary wave is characterized by the
development of a large diestrous follicle which either ovulates (diestrous ovulation),
luteinizes, or regresses [143]. The incidence of diestrous ovulations is extremely low in
pony mares [159] but can be as high as 21% in Thoroughbred mares [165]. It is generally
accepted that when a diestrous ovulation precedes luteolysis it can result in a prolonged
luteal phase (>30 days) as the immature corpus luteum has a reduced sensitivity to
endometrial PGF2α. However, the majority of the diestrous ovulations occur within the
first 10 days after ovulation [166], and therefore, are not associated with prolonged luteal
phases. To the authors’ knowledge, relative little has been published about the effect of
diestrous ovulations on estrous cycle characteristics in light horse mares. Therefore, the
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objectives of this study were (i) to determine age-related differences in follicular
dynamics, endocrine profiles, and primordial follicles (ii) to examine the influence of
antral follicle count on age-related changes in follicular parameters, and (iii) to examine
the effect of diestrous ovulations on follicular parameters and progesterone
concentrations.

5.2 Materials and Methods
5.2.1 Animal procedures
All animal procedures were approved by the Institutional Animal Care and Use
Committee of the University of Kentucky (#2010-067). Mares of mixed breeds, weighing
approximately 450-650 kg, were assigned to one of the following groups: young (n=10,
3-8 yr), middle-aged (n=16, 9-18 yr), or aged (n=19, 19-27 yr) mares. This study was part
of a larger experiment that examined the relationship between anti-Müllerian hormone,
antral follicle count, and age in mares [160]. Briefly, mares were examined using
transrectal ultrasonography during two consecutive estrous cycles. Ultrasound
examinations were conducted every-other day for 14 days after ovulation and then daily
until the subsequent ovulation. Follicular growth was monitored by recording two
dimensions (width and height) of the six largest follicles and the location of all recorded
follicles was drawn on an ovarian map. On day 12 of each estrous cycle, antral follicle
count (AFC) was determined as previously described [160]. Mares were classified as low,
medium, and high AFC based upon the interquartile ranges for AFC. Mares with a
detectable corpus luteum and turgid uterine tone that did not return to estrus by day 22
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post ovulation were given prostaglandin F2α (Lutalyse®, dinoprost tromethamine, 5 mg
intramuscularly) and data from that estrous cycle were excluded from the analysis. Daily
blood samples were collected by jugular venipuncture into heparinized tubes between 8
and 9 AM. Plasma samples obtained after centrifugation (1200 x g, 10 min) were stored
at -20°C until analysis for progesterone and follicle stimulating hormone (FSH). After
completion of the study, ovaries were removed from six young mares (age range: 3-8 yr)
and four aged (age range: 19-26 yr) mares for determination of the number of primordial
follicles. The ovary was separated from the oviduct and mesovarium, and sectioned into
0.8-cm transverse slices starting at the cranial pole of the ovary. All ovarian slices were
submerged and stored in formalin until further processing.

5.2.2 Follicular parameters and dynamics
The following reproductive parameters were determined: inter-ovulatory interval, length
of the luteal and follicular phase, day of luteolysis, day of follicle deviation, diameter of
the dominant follicle at deviation, growth rate of the emerging and dominant follicle,
diameter of the pre-ovulatory follicle two days (d-2) and one day (d-1) prior to ovulation
(day of ovulation = d0), number of major follicular waves per estrous cycle, number of
diestrous ovulations and number of estrous ovulations. The inter-ovulatory interval was
the time between two consecutive ovulations each associated with a different estrous
period [143]. The length of the luteal and follicular phase was determined by calculating
the number of days from ovulation to luteolysis, and between luteolysis and subsequent
ovulation, respectively. The last day of the estrous cycle with a progesterone
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concentration greater than 1 ng/mL was assigned as the day when luteolysis occurred
[167]. The day of deviation was determined as described by Gastal et al. [168]. The
growth rate of the dominant follicle was determined for two different time periods: from
deviation until two days prior to ovulation (dev. to d-2), and from two days prior to
ovulation to one day prior to ovulation (d-2 to d-1). The growth rate of dominant follicle
(from dev. to d-2) was calculated by dividing the difference between the diameter of the
pre-ovulatory follicle two days prior to ovulation and the diameter of dominant follicle at
deviation by the number of days between those two time points. The growth rate of the
emerging follicle was determined by calculating the mean growth of the largest growing
follicle from the time when follicular growth was identified until deviation. A major
follicular wave was identified when the largest growing follicle reached a diameter of at
least 28 mm [143].

5.2.3 Determination of plasma progesterone and FSH concentrations
Plasma progesterone concentrations were determined in all mares on day 0, 2, 4, 6, 8, 10,
and 12 and daily around the anticipated time of luteolysis during both estrous cycles.
Concentrations of progesterone were measured in duplicate using an enzyme-linked
immunosorbent assay, as described and validated by Munro et al. [169]. The limit of
sensitivity of the progesterone assay was 0.12 ng/mL. The intra- and inter-assay
coefficient of variation for progesterone concentrations was 7.5%, and 13.1%,
respectively.
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Plasma FSH concentrations were measured on alternating days in a subset of young
(n=4), middle-aged (n=4), and aged (n=6) mares with a single major ovulatory wave
during one estrous cycle. Plasma FSH concentrations were determined using a
radioimmunoassay as described in detail by Yoon et al. [170]. Data were normalized to
the mean inter-ovulatory interval of all mares using a method described by Carnevale et
al.[156]. The sensitivity of the FSH assay was 0.5 ng/mL. The intra- and inter-assay
coefficient of variation was 2.6 and 6.5 %, respectively.

5.2.4 Determination of primordial follicle counts
Determination of primordial follicle counts was performed by selecting the middle
section of each ovary for sampling. From this section a one-by-one cm tissue section was
removed from the center of the ovarian section and embedded in paraffin. Paraffin
embedded tissues were sectioned (8 µm) using a rotary microtome, and each 40th section
was mounted on a microscope slide. All slides were stained with hematoxylin and eosin.
Bright field microscopy (200 x magnification) was used to examine stained slides for the
presence of primordial follicles which were only counted if the nucleus of the oocyte was
present in the section.

5.3 Statistical analysis
Three aged mares were excluded from the analysis because the inter-ovulatory interval
was longer than 30 days (> 3 standard deviations away from the mean inter-ovulatory
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interval). Furthermore, one middle-aged and one aged mare were excluded from the
analysis because intra-uterine fluid was present during diestrus resulting in premature
luteolysis. The influence of age on the inter-ovulatory interval, length of the luteal and
follicular phase, as well as the day of luteolysis and deviation was examined using a
mixed model with mare as a random effect and age group, number of major follicular
waves, and estrous cycle number as fixed effects. A mixed model was also used to
examine the effect of age group on the growth rate of the emerging follicle, the growth
rate of dominant follicle, the diameter of the dominant follicle at deviation, and the
diameter of pre-ovulatory follicle. Within different age groups, differences in the growth
rate between the emerging follicle and dominant follicle, and differences in the growth
rate of the dominant follicle with respect to the days prior to ovulation (from dev. to d-2
versus from d-2 to d-1) was examined during each estrous cycle using a paired t-test. A
chi-square test was used to examine the effect of age on the number of major follicular
waves and ovulations for each estrous cycle. The influence of AFC on the inter-ovulatory
interval, length of the follicular phase, and day of deviation was determined using a
mixed model with mare as random effect and AFC group, age, the interaction of age by
AFC group, number of major follicular waves and estrous cycle number as fixed effects.
As a different estrous cycle without a diestrus ovulation from the same mare was
available for each estrous cycle with a diestrus ovulation, a paired t-test was used to
compare the inter-ovulatory interval, follicular and luteal phase duration, and the day of
deviation between estrous cycles with and without a diestrous ovulation. A mixed model
with estrous cycle day, number of corpora lutea, age group, and the interaction of estrous
cycle day by age group as fixed effects and mare as random effect was used to evaluate
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the influence of age group on plasma progesterone concentrations during both estrous
cycles and a Fisher’s protected least-significant difference (LSD) used for post hoc
analysis. The influence of age group on plasma FSH concentrations was determined
using a mixed model with estrous cycle day, age group, and the interaction of estrous
cycle day by age group as fixed effects and mare as random effect. A mixed model with
estrous cycle day, follicular wave (diestrous ovulation versus no diestrous ovulation), and
the interaction of estrous cycle day by follicular wave as fixed effects and mare as
random effect was also used to compare progesterone concentrations between estrous
cycles with and without a diestrous ovulation and Fisher’s protected LSD was used as
post hoc test. Differences in primordial follicle counts in the ovarian section from young
and aged mares were examined using the Wilcoxon signed rank test. All statistical
analyses were performed using JMP version 10.0 (SAS Institute; Cary, North Carolina).

5.4 Results
5.4.1 Follicular parameters and dynamics
5.4.1.1 Effect of age on estrous cycle parameters
Inter-ovulatory intervals were significantly longer in aged mares (P<0.04) than in young
mares (Table 5.1). Likewise, the length of the follicular phase was longer and the day of
follicle deviation occurred later (P<0.02) in aged mares than in young or middle-aged
mares while no significant differences were observed in the length of luteal phase
between young, middle-aged or aged mares. The diameter of the dominant follicle at
deviation was not significantly different in young, middle-aged or aged mares.
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Prostaglandins were administrated to two middle-aged and five aged mares at day 22
post-ovulation because they did not return to estrus. Progesterone concentration in all
those mares was greater than 1 ng/mL at the time of prostaglandinF2α administration.
Diestrous ovulations were associated with prolonged luteal phases (22 days) in the two
middle-aged mares but diestrous ovulations did not occur in any of the five aged mares.
The number of major follicular waves per estrous cycle was not significantly associated
with age group during the first estrous cycle; however, two follicular waves were less
frequently observed in aged mares than in young or middle-aged (P<0.05) mares during
the second estrous cycle. The number of ovulations and the growth rate of the emerging
and dominant follicles (from dev. to d-2, and from d-2 to d-1) were not significantly
different between young, middle-aged or aged mares. Within each age group, the growth
rate of emerging follicles was not significantly different than the growth rate of the
dominant follicle (dev. to d-2) whereas the growth rate of the dominant follicle (dev. to d2) was higher (P<0.05) than the growth rate of the dominant follicle on the last day prior
to ovulation (d-2 to d-1). Finally, the diameter of the pre-ovulatory follicle had a
tendency (P<0.08) to be smaller in aged mares than in middle-aged mares.
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Table 5.1 Follicular parameters and estrous cycle characteristics in young, middle-aged
and aged mares. Data are expressed as mean ± s.e.m. Different letters indicate statistical
significant differences. Statistical significance was set at P<0.05.
Age group
Reproductive parameters

Young

Middle-aged

Aged

(3-8 yrs)

(9-18 yrs)

(19-27 yrs)

Inter-ovulatory interval (days)

20.9 ± 0.5 a

21.6 ± 0.4 a,b

23.0 ± 0.8 b

Luteal phase (days)

15.6 ± 0.4 a

15.7 ± 0.3 a

16.4 ± 0.4 a

Follicular phase (days)

5.3 ± 0.3 a

5.8 ± 0.4 a

7.2 ± 0.5 b

Day of deviation

14.2 ± 0.6 a

13.1 ± 0.8 a

16.7 ± 0.7 b

Follicle size (mm) at deviation

24.5 ± 0.5 a

24.0 ± 0.7 a

23.7 ± 0.5 a

3.0 ± 0.2 a

3.0 ± 0.1 a

2.6 ± 0.2 a

3.0 ± 0.2 a

2.8 ± 0.2 a

2.9 ± 0.2 a

1.6 ± 0.3 a

0.8 ± 0.4 a

1.5 ± 0.4 a

39.4 ± 0.7 a

40.6 ± 0.6 a

37.8 ± 0.7 a

Growth rate (mm/day)
emerging follicle
Growth rate (mm/day)
dominant follicle
(dev. to d-2)
Growth rate (mm/day)
dominant follicle
(d-2 to d-1)
Diameter (mm) of the preovulatory follicle (d-1)
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5.4.1.2 Effect of antral follicle count on age-related changes in estrous cycle
parameters
Mare age (P<0.0004), the number of major follicular waves (P<0.007), and the
interaction of age by AFC group (P<0.008) had an influence on the inter-ovulatory
interval as well as the length of follicular phase but not on the day of deviation. As mare
age increased, the increase in the inter-ovulatory interval and the length of the follicular
phase was significantly associated with the number of antral follicles; mares with a low
number of antral follicles had a longer inter-ovulatory interval and a longer follicular
phase than mares with a medium or high number of antral follicles.

5.4.1.3 Effect of a diestrous ovulations on estrous cycle parameters
The overall incidence of a two-wave estrous cycle was 22.8 %. The incidence of a major
secondary ovulatory wave (characterized by the occurrence of a diestrous ovulation)
(15.2%) was twice as common as major secondary anovulatory wave (7.6%). Irrespective
of whether the secondary follicular wave is ovulatory or anovulatory, mares with a twowave estrous cycle had a longer inter-ovulatory interval (P=0.003) as well as longer luteal
(P<0.04) and follicular phases (P<0.02) compared to mares with a one-wave estrous
cycle. Furthermore, the day of deviation (P<0.005) occurred later in mares with a twowave estrous cycle than in mares with a one-wave estrous cycle. Two-wave estrous
cycles with a secondary ovulatory follicular wave (Table 5.2) had a longer interovulatory interval (P<0.001) and follicular (P<0.02) and luteal phase (P<0.0001) while
the day of deviation occurred later (P<0.0009).
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Table 5.2 Follicular parameters of mares with a one-wave estrous cycle (no diestrous
ovulation) and a two-wave estrous cycle with a secondary ovulatory follicular wave
(diestrous ovulation). Data are presented as mean ± s.e.m. Different letters indicate
statistical significant differences (P<0.05)
Reproductive

No diestrous ovulation

Diestrous ovulation

19.3 ± 0.4 a

22.7 ± 0.5 b

Follicular phase (days)

4.2 ± 0.4 a

6.0 ± 0.6 b

Luteal phase (days)

15.1 ± 0.3 a

16.7 ± 0.5 b

Day of deviation (day)

10.2 ± 1.0 a

15.4 ± 0.5 b

parameter
Inter-ovulatory interval
(days)

5.4.2 Plasma progesterone and FSH concentrations
5.4.2.1 Effect of age
During the first estrous cycle, plasma progesterone concentrations were related to estrous
cycle day (P<0.0001), number of corpora lutea (P<0.0001), and age group (P=0.08) while
the interaction of estrous cycle day by age group was not significant. Mares with two
corpora lutea had higher progesterone concentrations than mares with one corpus luteum.
Furthermore, plasma progesterone concentrations had a tendency to be higher in middleaged mares than in young mares (Figure 5.1). During the second estrous cycle, plasma
progesterone concentrations were significantly related to estrous cycle day (P<0.0001),
number of corpora lutea (P<0.0001), age group (P=0.02), and the interaction of estrous
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cycle day by age group (P=0.02). Plasma progesterone concentrations were significantly
higher on day 6, 8, and day 10 in aged mares compared to young and middle-aged mares
(Figure 1). Although plasma FSH concentrations appeared to be higher in aged mares
during the follicular phase (Figure 5.2), neither age group nor the interaction of age group
by estrous cycle day was significant.

Figure 5.1 Plasma progesterone concentrations across two consecutive estrous cycles in
young (dotted line), middle-aged (dashed line), and aged (solid line) mares. Plasma
progesterone concentrations during the first estrous cycle are shown on the left, while the
image on the right represents plasma progesterone concentrations during the second
estrous cycle. Data are presented as mean ± s.e.m. Asterisks indicate statistical significant
differences (P<0.05).
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Figure 5.2 Mean plasma FSH concentrations during one estrous cycle in a subset of
young (n=4), middle-aged (n=4), and aged mares (n=6). The solid, dashed, and dotted
line represent old mares, middle-aged mares, and young mares, respectively. Data are
presented as mean ± s.e.m.

5.4.2.2 Effect of a diestrous ovulation on peripheral progesterone concentration
Plasma progesterone concentrations were significantly associated with the day of the
estrous cycle (P<0.0001) as well as the interaction of estrous cycle day by the number of
follicular waves (P<0.0001) although the progesterone concentrations were not associated
with the number of follicular waves alone. Plasma progesterone concentrations were
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significantly higher on day 10, 12, 14, and 16 in cycles with a diestrous ovulation than in
cycles without a diestrous ovulation (Figure 5.3).

Figure 5.3 Mean plasma progesterone concentrations in mares with (solid line) and
without a diestrus ovulation. Data are presented as mean ± s.e.m. Asteriks indicate
statistical significant differences (P<0.05)

5.4.3 Primordial follicle counts
Primordial follicles in ovarian tissue were characterized histologically by a single layer of
flattened granulosa cells surrounding an oocyte. In several cases, a dark stained nucleolus
can be detected within nucleus of oocyte (Figure 5.4). The number of primordial follicles
varied widely within young (median: 227, range: 19-700) and aged mares (median: 0,
range: 0-46), and the number of primordial follicles was higher (P<0.02) in young mares
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than in aged mares. No primordial follicles were detected in 3 of the 4 aged mares even
though all mares included in this study were cyclic mares.

Figure 5.4 A histological image of a primordial follicle in equine ovarian tissue. The
primordial follicle consist of a single layer of flattened granulosa cells (arrowhead)
surrounding a oocyte which contains a nucleus. The darkly stained nucleolus (arrow) is
visible at the periphery of the nucleus.
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5.5 Discussion and conclusion
To the authors’ knowledge, this is the first report to evaluate age-related changes in
estrous cycle parameters in light horse mares in relationship with putative ovarian reserve
based upon antral follicle counts. As noted in a number of other mammals, the number of
primordial follicles not only decreases with age but also varies widely within the same
age group [95, 171]. This difference likely reflects differences in ovarian reserve that
appear to be established early in life and which ultimately affect reproductive aging
variably across individuals.

In general, age-associated changes in estrous cycle parameters in light horse mares in the
current study were similar to those reported previously in pony mares [111, 156, 157].
Prolonged inter-ovulatory intervals in aged mares were attributed to a longer follicular
phase and not to changes in luteal phase length. The day of follicle deviation was later in
older mares likely due to a delay in the emergence of the major primary follicular wave
[172]. The growth rate of the emerging or dominant follicle between young, middle-aged
and aged mares was similar although aged mares had a tendency to ovulate smaller
follicles than middle-aged mares. This observation is consistent with a clinical study
showing that older Thoroughbred mares ovulate smaller follicles [173]. Although mean
luteal phase length was not different across age groups, five aged and two middle-aged
mares had a prolonged luteal phase. In two middle-aged mares, prolonged luteal phase
was associated with a diestrous ovulation with subsequent maintenance of an immature
corpus luteum. In aged mares, diestrous ovulations were not identified and the cause of
prolonged maintenance of the CL was not apparent. Neely et al. demonstrated that
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luteolysis can be compromised in mares with chronic endometritis resulting in a
prolonged luteal phase [174], and this may have been the cause in the older mares in the
current study.

Although there were clear age-related effects on estrous cycle parameters, these data also
demonstrate an effect of AFC on follicular dynamics. As mare age increased, mares with
low AFC had longer inter-ovulatory intervals and longer follicular phases than mares
with medium or high AFC. This observation suggests that follicular reserve in older
mares may influence changes in follicular phase parameters and argues that reproductive
age and calendar age are distinct variables in the mare. Differences between reproductive
and calendar age are well described in
women [98, 161]. The age at which menopause varies widely among women [175]. This
is thought to be the result of inherent differences in the number of primordial follicles at
birth as well as variations in the rate of follicular depletion throughout life [98]. One of
determining factors of ovarian senescence in aged broodmares is the remaining number
of primordial follicles (follicular reserve) in the ovary. The lower number of primordial
follicles in the ovarian tissue of aged mares indicates that the ovarian reserve of mares
decreases with mare age, and supports the results of a recent study demonstrating that
primordial follicle counts decreases with mare age [176]. Irrespective of the age-related
decline in primordial follicles, the number of primordial follicles varied widely between
mares of the same age group. This wide range in the number of primordial follicles is in
accordance with an earlier study by Driancourt et al. [112] and suggests the presence of
inherent differences in the population of primordial follicles among mares. Consequently,
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this finding could potentially explain differences in mare age at onset of ovarian
senescence and highlights the necessity of differentiating the reproductive age of a mare
from its chronological age.

Based upon the methodology used in the current study, it was not possible to provide a
robust estimate for the number of primordial follicles remaining in the ovary of mares
across different age groups. The use of an ovarian biopsy, as in the current study, has
been proposed as a method to estimate follicular reserve in mares [177] however, the
methodology employed proved difficult to reliably detect primordial follicles in the ovary
from older mares. The distribution of primordial follicles in the ovary of older mares has
not been characterized and available sampling techniques would require that the entire
ovary be examined in order to provide a reliable estimate of follicular reserve in the older
mare. A valuable alternative to determine the size of the follicular pool is stereology
[178], a technique that employs systemic random sampling in which each part of ovary
has an equal chance to be included. Still, the usefulness of this technique in counting
primordial follicles has not been described in the light horse mares.

Besides age-related differences in the number of primordial follicles, reproductive aging
in light horse mares was also associated with changes in luteal activity Differences in
progesterone concentrations were detected between young, middle-aged and aged mares
in contrast to a study in pony mares [156]. Concentrations of progesterone were
significantly higher in aged mares during the second estrous cycle. Vanderwall et al. also
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measured progesterone concentrations during two consecutive estrous cycles in young
and aged mares and, likewise, found that aged mares had higher progesterone
concentrations during the latter part of diestrus during one of two estrous cycles [179].
However, without knowing regulatory factors that influence progesterone production in
the mare, it is difficult to explain why aged mares have higher progesterone
concentrations.

In contrast to peripheral progesterone concentrations, circulating FSH concentrations
were not significantly influenced by age even though FSH concentrations appeared
higher in aged mares during the follicular phase. Studies in pony mares have shown that
increased FSH concentrations are primarily observed in mares with an inter-ovulatory
interval close to or longer than 30 days or in mares that have reached reproductive
senescence when estrous cycles have ceased [103]. Mares with more advanced signs of
ovarian senescence were excluded from our study, and this could explain why FSH
concentrations were not significantly higher in the older age group. Based on the FSH
data in aged pony mares and the association between longer inter-ovulatory intervals and
low AFC in older mares detected in our study, we hypothesize that older mares with low
AFC have significantly higher FSH concentrations than older mares with medium or high
AFC. In fact, an inverse relationship between AFC and circulating FSH concentrations in
cattle is supportive of this hypothesis [180]. Thus, taking all the data into account,
monitoring changes in follicular parameters might be a more sensitive method to detect
early ovarian senescence than measuring circulating FSH concentrations.
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Finally, the occurrence of a major secondary follicular wave, particularly if accompanied
by a diestrous ovulation, significantly increased the length of both the follicular and luteal
phase of the estrous cycle in this study. The longer luteal phase in estrous cycles with a
diestrous ovulation might indicate that the process of luteolysis is delayed. Although the
overall progesterone concentration was not significantly different between estrous cycles
with and without a diestrous ovulation, progesterone concentrations were significantly
higher immediately prior to and around the expected time of luteolysis. As a diestrous
ovulation usually occurs during the early to mid-luteal phase, it will take several days
before the progesterone production from this immature corpus is markedly increased.
Therefore, it is not surprisingly that progesterone concentrations are only higher during
the latter part of the luteal phase in estrous cycles with a diestrous ovulation.

In conclusion, changes in follicular parameters in light horse mares with reproductive
aging are, to a large extent, comparable with changes noted previously in pony mares.
This study is the first to note, however, that antral follicle count is closely linked to agerelated changes in follicular parameters. In addition to the wide variation in the number
of primordial follicles between mares of the same age, a decrease in the ovarian reserve is
present in older mares. As changes in follicular parameters occur prior to changes in the
endocrine profiles, monitoring follicular parameters might be a more sensitive method to
detect early stages of ovarian senescence than measuring circulating hormone
concentrations. Finally, estrous cycles with diestrous ovulations are characterized by a
longer inter-ovulatory interval in which both the luteal and follicular phase are prolonged.
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Chapter Six: General conclusions
Research presented in this dissertation examined physiological variations and clinical
applications of anti-Mullerian hormone (AMH) in the stallion and mare. In addition,
molecular and hormonal changes in the equine follicle with regards to antral follicle
count (AFC) and follicular development as well as age-related changes in follicular
parameters and ovarian reserve were evaluated.

The methodological and biological validation of a commercially available human AMH
assay for the horse was based upon dilutional parallelism and the disappearance of AMH
after castration. Validation of this heterologous assay was an important step to reliably
assess variations in serum AMH concentrations in male horses with regards to pubertal
development, season, and gonadal status. As in humans, concentrations of AMH were
higher in pre-pubertal colts than in post-pubertal stallions. This finding suggests that
AMH declines during puberty but the underlying mechanism of this decline was not
determined. Although AMH concentrations were higher prior to puberty, concentrations
of AMH remain relative high in intact mature stallions compared to humans. This unique
feature could indicate that AMH plays an important role in testicular function or
steroidogenesis in the postpubertal stallion. The seasonal variations in AMH in intact
mature stallions support this hypothesis. Moreover, an increase in AMH concentrations
during the breeding season likely coincides with an increased production of spermatozoa.
Therefore, concentrations of AMH could be a reflection of either Sertoli cell number or
function. Nonetheless, whether AMH can be used to monitor the process of
spermatogenesis in intact, mature stallions still remains to be determined. On the other
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hand, the usefulness of AMH as biomarker for the presence of testicular tissue was
clearly documented. Diagnosis of cryptorchidism can be a challenge in equine practice
especially after a questionable cryptorchid castration or in case of inconclusive endocrine
test result. Therefore, the availability of an additional reliable marker for cryptorchidism
can be useful for equine practitioners. As for any diagnostic assay, knowing the
sensitivity and specificity of the assay is imperative. Unfortunately, although sensitivity
could be determined in the current study, we were unable to establish conclusive
information concerning specificity. Nonetheless, the Sertoli cell specific origin of AMH
as well as the higher concentrations of AMH in cryptorchid stallions than intact stallions
suggests that AMH is particularly valuable as diagnostic marker for cryptorchidism.

The clinical utility of AMH was not limited to diagnosing cryptorchidism in stallions.
Anti-Müllerian hormone also appears to be a useful biomarker for ovarian reserve in
middle-aged and aged mares as indicated by the moderate to strong correlation between
AMH and AFC. The wide variation in AMH between mares of the same age likely
attributes to differences in follicular reserve between mares while the lower
concentrations of AMH in aged mares support an age-related decline in ovarian reserve.
Furthermore, the high repeatability of AMH within and across estrous cycles renders
AMH suitable as biomarker for ovarian reserve. On the other hand, the inability to detect
a significant relationship between AFC and AMH in young mares was unexpected. It is
unclear if small sample size could have influenced the relationship between AFC and
AMH in young mares or if this represents a biological difference between young and
middle-aged or aged mares. To date, AMH has been compared to AFC which represents
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the total number of follicles detectable using ultrasonography. Still, it is likely that a large
proportion of follicles, more specifically atretic follicles, do not significantly contribute
to circulating AMH concentrations. Therefore, we hypothesize that circulating AMH
concentrations are also a reflection of the number of follicles recruited during each
follicular wave. However, without aspirating all antral follicles, it would be difficult to
test this hypothesis as newly recruited follicles are overlapped by larger, regressing
follicles. Irrespective, AMH appears to be a useful predictor of follicular reserve in
middle-aged and aged mares.

Variations in AFC and circulating AMH concentrations in mares are not only a reflection
of ovarian reserve but also appear to be related to follicular function as distinct molecular
differences were detected in growing follicles of mares with low AFC or low AMH
concentrations. Studies in other species have linked those molecular differences to
impaired ovarian function. More specifically, it has been shown that, in association with a
reduced expression of FSHR, the ovarian response to FSH is reduced in cows with low
AFC, and the lower expression of AMH is thought to be concomitant to a reduced oocyte
quality. In view of these data, the possibility exists that follicular function and oocyte
quality are impaired in mares with low AFC or low AMH.

Besides the relationship between AFC and molecular differences in the equine follicle,
follicular development was also associated with molecular and hormonal changes in the
equine follicle. The expression of AMH and a number of genes co-expressed with AMH,
known to play a role in the regulation of AMH, decreased during follicular development.

102

In accordance with molecular changes during follicular development, the synthesis of
AMH in the equine follicle also changed in relation to the stage of follicular development.
Circulating AMH concentrations were primarily associated with the numbers of antral
follicles between 6 and 20 mm, suggesting that the secretion of AMH appears to subside
around the time of follicle deviation. Indeed, concentrations of AMH in follicular fluid
were high immediately prior to follicle selection and decreased to low concentrations in
dominant follicles. So, it appears that follicular fluid AMH concentrations decline rather
rapidly after follicle deviation. This sharp decline in AMH could indicate that AMH plays
a role in follicle deviation in mares.

Finally, throughout the several different experiments, a large amount of evidence was
gathered indicating the reproductive age of a mare must be distinguished from the
chronological age. The large variation in AMH and AFC between old mares suggests that
there are considerable differences in follicular populations between old mares. Likewise,
the number of primordial follicles varied widely between mares of the same age which
also implies that there are inherent differences in the size of the follicular pool between
mares. Lastly, age-related changes in follicular parameters were closely linked to
differences in AFC. Taking all of these data into consideration, we conclude that the
variability in reproductive aging of mares is attributed to individual differences in
follicular populations. Therefore, measuring the concentration of AMH as well as
determining the number of antral follicle follicles should be an integral part in the
reproductive examination of older mares as it provides valuable information about the
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process of reproductive aging and could help veterinarians to predict the reproductive
lifespan of mares.

In conclusion, AMH can serve as a biomarker for cryptorchidism in stallions and ovarian
reserve in mares. In addition, impaired ovarian function as well as age-related changes in
follicular parameters in mares is linked to a low number of antral follicles.

Copyright @ Anthony N.J. Claes 2014
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